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A B S T R A C T
Background
Many people with schizophrenia do not achieve a satisfactory treatment response with just antipsychotic drug treatment and various
adjunct medications are used to promote additional response. The antiepileptic carbamazepine is one such drug.
Objectives
To evaluate the effects of carbamazepine and its derivatives for the treatment of schizophrenia and related psychoses.
Search methods
For the original versionwe searchedBiological Abstracts (1980-2001), TheCochrane Library (Issue 3, 2001), TheCochrane Schizophre-
nia Group’s Register of Trials (December 2001), EMBASE (1980-2001), MEDLINE (1966-2001), PsycLIT (1886-2001) and PSYN-
DEX (1974-2001). For the current update we searched the Cochrane Schizophrenia Group’s Register of Trials in March 2005 and in
December 2006. We also inspected references of all identified studies for further trials and contacted relevant pharmaceutical companies
and authors for additional data.
Selection criteria
We included all randomised controlled trials comparing carbamazepine or compounds of the carbamazepine family to placebo or
no intervention, whether as sole treatment or as an adjunct to antipsychotic medication for the treatment of schizophrenia and/or
schizoaffective psychoses.
Data collection and analysis
We extracted data independently. For homogenous dichotomous data we calculated random effects, relative risk (RR), 95% confidence
intervals (CI) and, where appropriate, numbers needed to treat (NNT) on an intention-to-treat basis. For continuous data, we calculated
weighted mean differences (WMD).
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Main results
The update search did not reveal any further studies that met our inclusion criteria. The number of included studies therefore remains
at ten with the number of participants randomised still 258. One study comparing carbamazepine with placebo as the sole treatment
for schizophrenia was abandoned early due to high relapse rate with 26 out of 31 participants relapsing by three months. No effect of
carbamazepine was evident with no difference in relapse between the two groups (1 RCT n=31, RR 4.1 CI 0.8 to 1.5).
Another study compared carbamazepine with antipsychotics as the sole treatment for schizophrenia. No differences in terms of mental
state were found when comparing 50% reduction in BPRS scores (1 RCT n=38, RR 1.2 CI 0.8 to 1.9). A favourable effect for
carbamazepine was found when more people who received the antipsychotic (perphenazine) had parkinsonism (1 RCT n=38, RR 0.03
CI 0.00 to 0.04, NNH 1 CI 0.9 to 1.4).
Eight studies compared adjunctive carbamazepine versus adjunctive placebo. Adding carbamazepine to antipsychotic treatment was as
acceptable as adding placebo with no difference between the numbers leaving the study early from each group (8 RCTs n=182, RR 0.5
CI 0.2 to 1.4). Carbamazepine augmentation was superior compared with antipsychotics alone in terms of overall global improvement,
but participant numbers were low (2RCTs n=38, RR 0.6 CI 0.4 to 0.9, NNT 2 CI 1 to 5). There were no differences for the mental
state outcome of 50% reduction in BPRS scores (6 RCTs n=147, RR 0.9 CI 0.7 to 1.1). Less people in the carbamazepine augmentation
group had movement disorders than those taking haloperidol alone (1 RCT n=20, RR 0.4 CI 0.1 to 1.0). No data were available for the
effects of carbamazepine on subgroups of people with schizophrenia and aggressive behaviour, negative symptoms or EEG abnormalities
or with schizoaffective disorder.
Authors’ conclusions
Based on currently available randomised trial-derived evidence, carbamazepine cannot be recommended for routine clinical use for
treatment or augmentation of antipsychotic treatment of schizophrenia. At present large, simple well-designed and reported trials are
justified especially if focusing on those with violent episodes and people with schizoaffective disorders or those with both schizophrenia
and EEG abnormalities.
P L A I N L A N G U A G E S U M M A R Y
Carbamazepine for schizophrenia
Schizophrenia is a serious mental illness which can cause people to change the way they sense and understand the world. It can be
very serious and continue to affect some people throughout their life. Although most people with this illness can be helped by taking
antipsychotic medication, 5-15% will continue to suffer from debilitating symptoms. For this group of people a variety of medical
options are available to reduce these symptoms, including adjusting the dose of medication, changing to another antipsychotic, or using
drugs other than antipsychotics.
Carbamazepine is a drug which has been used to treat epilepsy since the 1950s. It is also used as a mood stabiliser when people alternate
between very ‘high’ and depressed moods (bi-polar affective disorder). This review looks at the effectiveness of carbamazepine when
compared to no active medication (placebo), an antipsychotic, or when it is used in addition to an antipsychotic in clinical trials on
people who have schizophrenia both with additional mood problems (schizoaffective disorder), and without.
Ten trials were found which included a total of 258 people. All except one of these studies were carried out in a hospital setting. One
small trial compared carbamazepine treatment with placebo (31 people) and found that there was no significant difference between
these in respect to preventing relapse, mental state or development of adverse effects. Another single study of 38 people compared
carbamazepine (as a single treatment) with the antipsychotic perphenazine (as a single treatment) and found no significant difference
between the people in the two groups except that those on perphenazine were more likely to have movement side effects and be taking
medication for them.
The remainder of the trials compared antipsychotic plus carbamazepine with antipsychotic plus placebo. Two of these trials (38 people)
showed that when carbamazepine was taken with an antipsychotic, there was a general improvement in over half of these people.
However, for the majority of the outcomes for which there was acceptable data, there was no significant difference between the two
groups. Since all of these trials were small, there is not enough data to clarify whether carbamazepine reduces symptoms without giving
too many adverse effects in people with schizophrenia and schizoaffective disorders who are resistant to treatment with antipsychotics
alone. A larger well designed trial may provide more robust evidence to support the treatment options for these people.
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(Plain language summary prepared for this review by Janey Antoniou of RETHINK, UK www.rethink.org).
B A C K G R O U N D
Despite the introduction of antipsychotic (neuroleptic) medica-
tion in the 1950s, there is still a sizeable minority of people with
schizophrenia and related conditions that do not have complete
remission of symptoms (Schooler 1993). Over the last 40 years a
variety of adjunctive treatments have beenused to treat schizophre-
nia (Christison 1991). These are often used in addition to an-
tipsychotics, in order to augment any alleviation of symptoms of
schizophrenia, but can be used instead of antipsychotics. Treat-
ments such as lithium (indicated for bipolar affective disorder),
carbamazepine (or related compounds such as oxcarbazepine),
benzodiazepines, beta-blockers (Ahonen 1998) and electroconvul-
sive therapy (Tharyan 2002) have all been used for people whose
psychoses did not respond to traditional therapy. The situation
has improved somewhat in recent years with the re-introduction
of clozapine which has proven efficacy for those that have not re-
sponded to traditional medications (Wahlbeck 1998). However,
many people with psychoses have sub-optimal responses to treat-
ment, and clinicians are faced with the choice of changing to al-
ternate types of medication, or augmenting existing neuroleptics
with other drugs or treatments.
Carbamazepine is traditionally used for the treatment of epilepsy,
but is also used to prevent relapse, as a ’mood stabiliser’, in bipolar
affective illness in a similar fashion to lithium (Dardennes 1995).
Oxcarbazepine is a related compound that is said to be an im-
provement on the older ’parent’ drug (Tiihonen 1995). In this
review we do not examine the efficacy of carbamazepine for mood
disorders and the affective psychoses. However in two companion
reviews the impact of lithium and benzodiazepines as sole or ad-
junctive treatment for schizophrenia and schizoaffective psychoses
is examined.
O B J E C T I V E S
To examine whether carbamazepine/oxcarbazepine alone is an ef-
fective treatment for schizophrenia and schizoaffective psychoses
and whether carbamazepine/oxcarbazepine augmentation of neu-
roleptic medication is an effective treatment for the same illnesses.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included all relevant randomised controlled trials.Where a trial
was described as ’double-blind’, but it was implied that the study
was randomised, we included the trial in a sensitivity analysis. If
there was no substantive difference within primary outcomes (see
’types of outcome measures’) when these ’implied randomisation’
studies were added, then we included these in the final analysis.
If there was a substantive difference, we only analysed clearly ran-
domised trials and described the results of the sensitivity analysis
in the text. We excluded quasi-randomised studies, such as those
allocating by using alternate days of the week.
Types of participants
People with schizophrenia, schizophreniform psychoses, delu-
sional disorder and schizoaffective psychoses as diagnosed by any
criteria.
Types of interventions
1. Carbamazepine/oxcarbazepine alone: any dose.
2. Placebo (or no intervention).
3. Carbamazepine/oxcarbazepine in combination with any an-
tipsychotic treatment: any dose.
4. Placebo (or no intervention) in combination with any antipsy-
chotic treatment.
5. Antipsychotics alone: any dose.
Types of outcome measures
1. Leaving the study early
1.1 For specific reasons
1.2 For general reasons
2. Service utilisation
2.1 Hospital admission
2.2 Days in hospital
2.3 Change in hospital status
3. Global state
3.1 Relapse - as defined by each of the studies
3.2 Time to relapse
3.3 No clinically important change in global state*
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3.4 Not any change in global state
3.5 Average endpoint global state score
3.6 Average change in global state scores
4. Mental state
4.1 General mental state
4.1.1 No clinically important change in general mental state - as
defined by each of the studies
4.1.2 Not any change in general mental state
4.1.3 Average endpoint general mental state score
4.1.4 Average change in general mental state scores
4.2 Specific aspects of mental state
4.2.1 No clinically significant response in positive symptoms - as
defined by each of the studies
4.2.2 Not any change in positive symptoms
4.2.3 Average endpoint positive symptom score
4.2.4 Average change in positive symptom scores
4.2.5 No clinically significant response in negative symptoms - as
defined by each of the studies
4.2.6 Not any change in negative symptoms
4.2.7 Average endpoint negative symptom score
4.2.8 Average change in negative symptom scores
4.2.9 No clinically significant response in depressive symptoms -
as defined by each of the studies
4.2.10 Not any change in depressive symptoms
4.2.11 Average endpoint depressive symptom score
4.2.12 Average change in depressive symptom scores
4.2.13 No clinically significant response in manic symptoms - as
defined by each of the studies
4.2.14 Not any change in manic symptoms
4.2.15 Average endpoint manic symptom score
4.2.16 Average change in manic symptom scores
5. Behaviour
5.1 General behaviour
5.1.1 No clinically important change in general behaviour
5.1.2 Not any change in general behaviour
5.1.3 Average endpoint general behaviour score
5.1.4 Average change in general behaviour scores
5.1.5 Compulsory administrations of treatment
5.1.6 Use of further doses of medication
5.2 Specific behaviours
5.2.1 Self-harm, including suicide
5.2.2 Injury to others
5.2.3 Aggression
5.2.3.1 No clinically important change in aggression
5.2.3.2 Not any change in aggression
5.2.3.3 Average endpoint aggression score
5.2.3.4 Average change in aggression scores
5.2.4 Self care
5.2.4.1 No clinically important change in self care
5.2.4.2 Not any change in self care
5.2.4.3 Average endpoint self care score
5.2.4.4 Average change in self care scores
5.2.5 Compliance
5.2.5.1 No clinically important change in compliance
5.2.5.2 Not any change in compliance
5.2.5.3 Average endpoint compliance score
5.2.5.4 Average change in compliance scores
6. Social functioning
6.1 No clinically important effects for social function
6.2 Not any effects for social function
6.3 Average endpoint social functioning score
6.4 Average change social functioning scores
6.5 Employment status during trial (employed / unemployed)
7. Adverse effects
7.1 Clinically important general adverse effects*
7.2 Any general adverse effects
7.3 Average endpoint general adverse effect score
7.4 Average change in general adverse effect scores
7.5 Clinically important change in specific adverse effects such as
movement disorders
7.6 Any change in specific adverse effects
7.7 Average endpoint specific adverse effects
7.8 Average change in specific adverse effects
7.9 Use of antiparkinsonian treatment
8. Sudden and unexpected death
9. Economic outcomes
9.1 Direct costs
9.2 Indirect costs
10. Satisfaction with treatment
10.1 Recipient of care not satisfied with treatment
10.2 Recipient of care average satisfaction score
10.3 Recipient of care average change in satisfaction scores
10.4 Carer not satisfied with treatment
10.5 Carer average satisfaction score
10.6 Carer average change in satisfaction scores
11. Quality of life
11.1 No clinically important change in quality of life
11.2 Not any change in quality of life
11.3 Average endpoint quality of life score
11.4 Average change in quality of life scores
11.5 No clinically important change in specific aspects of quality
of life
11.6 Not any change in specific aspects of quality of life
11.7 Average endpoint specific aspects of quality of life
11.8 Average change in specific aspects of quality of life
12. Pharmacokinetic interactions - change of haloperidol plasma-
levels.
* Primary outcomes of interest were overall improvement and side
effects.
We grouped all outcomes by time - short term (up to 12 weeks),
medium term (13 to 26 weeks) and long term (over 26 weeks).
Search methods for identification of studies
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#1. Update searches in March 2005 and in December 2006
For the update we searched the Cochrane Schizophrenia Group’s
Register of Trials (March 2005 and November 2006) using the
phrase: [((*carbama* or *amizepine* or *carbag* or *carbap* or
*carbaz* or *carbymal* or *carpaz* or *cephalon* or *degranol* or
*epitol* or *finlepsin* or *fokalepsin* or *hermolepsin* or *neuro-
tol* or *neurotop* or *nordotol* or *sirtal* or *tardotol* or *tegret*
or *teril* or *timonil* or *trimonil* or *trialeptal* or *trilpetal*)
in Ti, Ab and In fields in References) AND (carbama* in Inter-
vention field in Study)]
This register is compiled by systematic searches ofmajor databases,
hand searches and conference proceedings (see Group Module)
2. Original search
2.1 Electronic searching
2.1.1 We searched Biological Abstracts (January 1980 - August
2001) using the Cochrane Schizophrenia Group’s phrase for both
randomised controlled trials and schizophrenia (see Group search
strategy) combined with the phrase:
[and carbamazepine* or tegretol or tardotol or tegretal or
carbagamma or carbymal or carpaz or carbapin or degranol or fin-
lepsin or fokalepsin or hermolepsin or neurotol or neurotop or nor-
dotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil
or “10,11-dihydro-10-oxo-5H-dobenz[b,f ]azepine-5-carboxam-
ide” or “5H-dibenz[b,f ]azepine-5-carboxamide” or (GP near1
(49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trilep-
tal or “trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f ]azepine-
5-carboxamide”]
2.1.2 We searched The Cochrane Library (Issue 3, 2001) using
the phrase:
[and carbamazepine* or tegretol or tardotol or tegretal or
carbagamma or carbymal or carpaz or carbapin or degranol or
finlepsin or fokalepsin or hermolepsin or neurotol or neurotop
or nordotol or oxcarbazepine or sirtal or tardotol or timonil
or trimonil or “10,11-dihydro-10-oxo-5H-dobenz[b,f ]azepine-5-
carboxamide” or “5H-dibenz[b,f ]azepine-5-carboxamide” or (GP
and (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trilep-
tal or “trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f ]azepine-
5-carboxamide” or explode CARBAMAZEPINE / all]
2.1.3 We searched the Cochrane Schizophrenia Group’s Register
of Trials (December 2001) using the phrase:
[and carbamazepine* or tegretol or tardotol or tegretal or
carbagamma or carbymal or carpaz or carbapin or degranol or
finlepsin or fokalepsin or hermolepsin or neurotol or neurotop
or nordotol or oxcarbazepine or sirtal or tardotol or timonil
or trimonil or “10,11-dihydro-10-oxo-5H-dobenz[b,f ]azepine-5-
carboxamide” or “5H-dibenz[b,f ]azepine-5-carboxamide” or (GP
and (49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trilep-
tal or “trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f ]azepine-
5-carboxamide”or #42 = 684 or #42=20]
#42 is the intervention field within the register and 684 and 20
are the codes for carbamazepine.
2.1.4 We searched EMBASE (January 1980 - August 2001) using
the Cochrane Schizophrenia Group’s phrase for both randomised
controlled trials and schizophrenia (see Group search strategy)
combined with the phrase:
[and carbamazepine* or tegretol or tardotol or tegretal or
carbagamma or carbymal or carpaz or carbapin or degranol or fin-
lepsin or fokalepsin or hermolepsin or neurotol or neurotop or nor-
dotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil
or “10,11-dihydro-10-oxo-5H-dobenz[b,f ]azepine-5-carboxam-
ide” or “5H-dibenz[b,f ]azepine-5-carboxamide” or (GP near1
(49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trilep-
tal or “trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f ]azepine-
5-carboxamide”or explode CARBAMAZEPINE / all]
2.1.5 We searched MEDLINE (January 1966 - August 2001)
using the Cochrane Schizophrenia Group’s phrase for both ran-
domised controlled trials and schizophrenia (see Group search
strategy) combined with the phrase:
[and carbamazepine* or tegretol or tardotol or tegretal or
carbagamma or carbymal or carpaz or carbapin or degranol or fin-
lepsin or fokalepsin or hermolepsin or neurotol or neurotop or nor-
dotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil
or “10,11-dihydro-10-oxo-5H-dobenz[b,f ]azepine-5-carboxam-
ide” or “5H-dibenz[b,f ]azepine-5-carboxamide” or (GP near1
(49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trilep-
tal or “trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f ]azepine-
5-carboxamide”or explode CARBAMAZEPINE / all]
2.1.6 We searched PsycLIT (1886 - August 2001) using the
Cochrane SchizophreniaGroup’s phrase for both randomised con-
trolled trials and schizophrenia (see Group search strategy) com-
bined with the phrase:
[and carbamazepine* or tegretol or tardotol or tegretal or
carbagamma or carbymal or carpaz or carbapin or degranol or fin-
lepsin or fokalepsin or hermolepsin or neurotol or neurotop or nor-
dotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil
or “10,11-dihydro-10-oxo-5H-dobenz[b,f ]azepine-5-carboxam-
ide” or “5H-dibenz[b,f ]azepine-5-carboxamide” or (GP near1
(49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trilep-
tal or “trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f ]azepine-
5-carboxamide”or explode “CARBAMAZEPINE” / all]
2.1.7We searchedPSYNDEX(January 1974 -August 2001) using
the Cochrane Schizophrenia Group’s phrase for both randomised
controlled trials and schizophrenia (see Group search strategy)
combined with the phrase:
[and carbamazepine* or tegretol or tardotol or tegretal or
carbagamma or carbymal or carpaz or carbapin or degranol or fin-
lepsin or fokalepsin or hermolepsin or neurotol or neurotop or nor-
dotol or oxcarbazepine or sirtal or tardotol or timonil or trimonil
or “10,11-dihydro-10-oxo-5H-dobenz[b,f ]azepine-5-carboxam-
ide” or “5H-dibenz[b,f ]azepine-5-carboxamide” or (GP near1
(49.023 or 10.000 or 47.779 or 47.680)) or trialeptal or trilep-
tal or “trans-10,11-dihydro-10,11-epoxy-5h-dibenz[b,f ]azepine-
5-carboxamide]
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2.2 Reference lists
We searched all references of articles selected for inclusion for
further relevant trials.
2.3 Pharmaceutical companies
We contacted companies performing trials with carbamazepine to
obtain data on unpublished trials.
2.4 Personal contact
We contacted the first author of each included study for more data
of their study and any information regarding unpublished trials.
Data collection and analysis
[For definitions of terms used in this, and other sections, please
refer to the Glossary.]
1. Selection of trials
SL independently inspected all reports identified by the search and
JM re-inspected these to ensure reliable selection. Where agree-
ment could not be reached, we acquired the full report was for
more detailed scrutiny. Once the full reports were obtained we in-
dependently inspected them to assess their relevance to this review.
Again, if disagreement could not be resolved by discussion or from
published information, we added the article to those awaiting as-
sessment and contacted the authors of the study for clarification.
2. Assessment of methodological quality
We assessed the methodological quality of included trials in this
review using the criteria described in the Cochrane Handbook
(Higgins 2005) and the Jadad Scale (Jadad 1996). The former is
based on the evidence of a strong relationship among the potential
for bias in the results and the allocation concealment (Schulz 1995)
and is defined as below:
A. Low risk of bias (adequate allocation concealment)
B. Moderate risk of bias (some doubt about the results)
C. High risk of bias (inadequate allocation concealment)
The Jadad Scale measures a wider range of factors that impact on
the quality of a trial. The scale includes three items:
1. Was the study described as randomised?
2. Was the study described as double-blind?
3. Was there a description of withdrawals and drop outs?
Each item receives one point if the answer is positive. In addition, a
point can be deducted if either the randomisation or the blinding/
masking procedures describedwere inadequate or added if random
number generation adequate or blinding appropriate. Scores on
item 1 and 2 can therefore be 0, 1 or 2.
For the purpose of the analysis in this review, we included trials if
they met the criteria A or B of the Cochrane Handbook. We did
not us the Jadad scale to exclude trials in this review, but we used
it to explore potential heterogeneity as a result of trial quality.
3. Data collection
We independently extracted the data from included studies. Again,
we discussed any disagreement and documented decisions. When
this was not possible, we sought further information from authors
of the studies and did not enter data from these trials but added
them to the list of those awaiting assessment.
4. Data synthesis
4.1 Data types
Outcomes are assessed using continuous (for example changes on
a behaviour scale), categorical (for example, one of three categories
on a behaviour scale, such as ’little change’, ’moderate change’ or
’much change’) or dichotomous measures (for example, either ’no
important changes’ or ’important changes’ in a person’s behaviour).
Currently RevMan does not support categorical data so they were
presented only in the text of the review.
4.2 Incomplete data
For studies that did not specify the reasons for people leaving the
study early (dropped out), we assumed that these people had no
change in the clinical outcome variables. If over 50% of people
dropped out, and the study did not provide intention-to-treat
results for continuous data, we excluded these data.
4.3 Crossover design
We expected that some trials would use a crossover design. In order
to exclude the potential additive effect in the second ormore stages
on these trials, we only analysed data from the first stage.
4.4 Dichotomous - yes/no data
We carried out an intention to treat analysis. On the condition that
more than 50% of people completed the study, everyone allocated
to the intervention were counted, whether they completed the
follow up or not. We assumed that those who dropped out had
the negative outcome, with the exception of death.
Where possible efforts were made to convert outcome measures to
dichotomous data. This may be done by identifying cut off points
on rating scales and dividing subjects accordingly into ’clinically
improved’ or ’not clinically improved’. If the authors of a study
had used a designated cut off point for determining clinical effec-
tiveness we used this where appropriate.
For dichotomous outcomes, a relative risk (RR)with the 95% con-
fidence interval (CI) based on a fixed effects model was estimated.
This is different to previous versions of this review. The reason for
the change is that it has been shown that relative risks are more
intuitive to clinicians than odds ratios (Boissel 1999). Further-
more, clinicians tend to interpret odds ratios as relative risks. This
misinterpretation leads to an overestimate of effect (Deeks 2000).
When overall results were significant we calculated the Number
Needed to Treat (NNT) and/or the Number Needed to Harm
(NNH) as the inverse of the absolute risk difference.
4.5 Continuous data
4.5.1 Normally distributed data: Continuous data on outcomes
in trials relevant to mental health issues are often not normally
distributed. To avoid the pitfall of applying parametric tests to
non-parametric data the following standards were applied to data
derived from continuous measures of endpoint (’state’ data). The
criteria were used before inclusion:
i. standard deviations and means were reported in the paper or
were obtainable from the authors and ii. the standard deviation
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(SD), when multiplied by 2, was less than the mean (as otherwise
the mean was unlikely to be an appropriate measure of the centre
of the distribution) (Altman 1996). If a scale starts from a positive
value (such as PANSS which can have values from 30 to 210)
the calculation described above in ii) should be modified to take
the scale starting point into account. In these cases skewness is
present if 2SD>(S-Smin), where S is the mean score and Smin is
the minimum score. We did not enter data that did not meet the
first or second standard into RevMan software for analysis, but
reported the data in the text of the results section.
4.5.2 Scale derived data: A wide range of rating scales is available
to measure outcomes in mental health trials. These scales vary in
quality and many are questionably validated, or even ad hoc. It
is generally accepted that measuring instruments should have the
properties of reliability (the extent to which a test effectively mea-
sures anything at all) and validity (the extent to which a test mea-
sures that which it is supposed to measure). Before publication of
an instrument,most scientific journals insist that reliability and va-
lidity be demonstrated to the satisfaction of referees. We therefore
decided, as a minimum standard, not to include any data from a
rating scale in this review unless its properties had been published
in a peer-reviewed journal. In addition, we set the following min-
imum standards for rating scales; the rating scale should either be
i. a self-report or ii. completed by an independent rater or relative.
We may set more stringent standards for instruments in future
updates of this review.
Whenever possible we took the opportunity to make direct com-
parisons between trials that used the same measurement instru-
ment to quantify specific outcomes. Where continuous data was
presented from different scales rating the same effect, we presented
both sets of data and inspected the general direction of effect.
4.5.3 Endpoint versus change data: For continuous mean change
data (endpoint minus baseline) the situation is even more prob-
lematic. In the absence of individual patient data it is impossible
to know if change data is skewed. The RevMan meta-analyses of
continuous data are based on the assumption that the data are,
at least to a reasonable degree, normally distributed. It is quite
feasible that change data is skewed but, after consulting the ALL-
STAT electronic statistics mailing list, it was entered into RevMan
in order to summarise the available information. In doing this it
is assumed that either data were not skewed or that the analyses
within RevMan could cope with the unknown degree of skewness.
4.6 Individual patient data
For this update we requested the individual patient data from the
original authors. Most of these were data derived from the BPRS,
a scale measuring mental state. We tried to convert these results
to dichotomous data (see 4.3.1). As it seemed impossible to us to
predefine which level of reduction of the total score is clinically
meaningful, three levels were analysed: a relatively low level (at
least 20% BPRS reduction), an intermediate level (at least 35%
BPRS reduction) and a relatively high level (at least 50% BPRS
reduction).
4.7 Data display
We entered data into RevMan in such a way that the area to the
left of the line of no effect indicated a favourable outcome for
carbamazepine alone or carbamazepine augmentation.
4.8 Cluster trials
Studies increasingly employ ”cluster randomisation“ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra class correlation in clustered studies, leading to a ”unit
of analysis“ error (Divine 1992) whereby p values are spuriously
low, confidence intervals unduly narrow and statistical significance
overestimated. This causes type 1 errors (Bland 1997, Gulliford
1999).
Where clustering was not accounted for in primary studies, we
presented the data in a table, with a (*) symbol to indicate the pres-
ence of a probable unit of analysis error. in subsequent versions of
this review we will seek to contact first authors of studies to obtain
intra-class correlation co-efficients of their clustered data and to
adjust for this using accepted methods (Gulliford 1999). Where
clustering was incorporated into the analysis of primary studies,
we presented these data as if from a non-cluster randomised study,
but adjusted for the clustering effect.
We sought statistical advice and were advised that the binary data
as presented in a report should be divided by a ”design effect“. This
is calculated using themean number of participants per cluster (m)
and the intraclass correlation co-efficient (ICC) [Design effect=
1+(m-1)*ICC] (Donner 2002). If the ICC was not reported, we
assumed it to be 0.1 (Ukoumunne 1999).
If cluster studies had been appropriately analysed taking into ac-
count intra-class correlation coefficients and relevant data docu-
mented in the report, synthesis with other studies would have been
possible using the generic inverse variance technique.
5. Investigation for heterogeneity
Firstly, we visually inspected graphs to investigate the possibility of
statistical heterogeneity. This was supplemented using, primarily,
the I-squared statistic. This provides an estimate of the percent-
age of variability due to heterogeneity rather than chance alone.
Where the I-squared estimate was greater than or equal to 50%we
interpreted this as indicating the presence of considerable levels
of heterogeneity (Higgins 2005). The I-squared statistic has been
described to be a more appropriate indicator of heterogeneity than
the Chi-square test that was used in the previous version of the
review (Higgins 2005). If either the I-squared statistic was higher
than 50% or the p-value of the Chi-square test, for reasons of
consistency we did not deviate from the rule as to when the fixed
and when the random effect model has to be applied, although we
would now rather use the random effects model throughout.
6. Publication bias
We entered data from all included trials into a funnel graph (trial
effect versus trial size or ’precision’) in an attempt to investigate
the likelihood of overt publication bias. A formal test of funnel
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plot asymmetry (suggesting potential publication bias) was under-
taken, where appropriate (Egger 1997). Significance levels of p <
0.1 were set a priori to accept the presence of asymmetry. Where
only three or four studies reported an outcome or there was little
variety in sample size (or precision estimate) between studies tests
of asymmetry were not appropriate.
7. Where possible, we entered data in such a way that the area to
the left of the line of no effect indicated a favourable outcome for
carbamazepine.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Please also see tables of included and excluded studies.
1. Excluded studies
We excluded 89 studies. The main reasons for exclusion were that
studies were not randomised trials, or allocated in a way that was
too open to the inclusion of bias (n=42). Several papers, mainly
reviews, did not contain any original data (n=19), one other did
not include people with schizophrenia or similar disorders or and
five did not include a placebo or no-intervention group. This lat-
ter group all involved lithium as the comparator. One of these
five studies was the only trial which used oxcarbazepine instead
of carbamazepine. Two studies examined participants with several
diagnoses, but no data specifically for people with schizophrenia
only could be extracted (de Vogelaer 1981, Dehing 1968). Three
studies randomised appropriate participant groups to relevant in-
terventions, but no data could be extracted from the original pub-
lications (Kidron 1985, Klein 1984, Möller 1989). We contacted
the authors of these studies who replied explaining that the data
were no longer available; we therefore had to exclude these studies.
2. Studies awaiting assessment
We have not heard back from the author of the study classified as
awaiting assessment in the 2002 update (Lee 1996). In the 2005
update we found another potentially relevant study (Kamisada
1988), but it is only available as an abstract and the design is
unclear; we therefore classified it as awaiting assessment. We have
contacted the first author formore information, but did not receive
any reply.
3. Ongoing studies
We are not aware of any ongoing studies.
4. Included studies
We included ten studies in the current version of this review. Most
studies used a parallel group designs but Carpenter 1991, Llorca
1993, Svestka 1989 and Neppe 1983 were crossover studies. Of
the latter, we used only the results of the first phase.
4.1 Length of trials
One study was a medium-term study with a duration of 14 weeks
(Carpenter 1991) but all others were in the ’short-term’ category
being between one and six weeks long within a single treatment
phase.
4.2 Participants
These studies included a total of 258 people. Most suffered from
schizophrenia but there were also some with schizoaffective disor-
der (n=12), other diagnoses (n=3) and 23 patients where the diag-
nosis was not clearly indicated. Four studies included only people
with sub-types of serious mental illnesses: treatment resistant ill-
ness (Llorca 1993, Simhandl 1996), ”residual patients“ suffering
from negative symptoms (Nachshoni 1994) and ”psychotic pa-
tients with EEG abnormalities“ (Neppe 1983). Diagnostic criteria
varied to a considerable degree, because the studies were carried
out over a long period of time, but most studies used some sort of
standard diagnostic criteria. Where possible we excluded partici-
pants with affective disorder or dementia.
4.3 Setting
Only Carpenter 1991was undertaken in the community and all
others were carried out with people currently in hospital.
4.4 Study size
The number of people in each study was low and ranged from
between 13 and 41.
4.5 Interventions
One study examined carbamazepine as a sole agent in relapse pre-
vention (Carpenter 1991), and a second compared carbamazepine
as a sole treatment with perphenazine for acutely ill people with
schizophrenia (Svestka 1989). All other studies investigated carba-
mazepine as an adjunct to antipsychotic drug treatment. Themost
commonly used dose of carbamazepine was about 6600 mg day
and haloperidol was commonly used as the standard antipsychotic
treatment (doses ranging from 6-665 mg day).
4.6 Outcomes
In the original reports many different scales were used to assess
outcome parameters which makes the summation of results diffi-
cult. Furthermore, different ways of analysing the same scale were
used, for example, comparison of mean changes or comparison
of endpoint values. Only one study (Neppe 1983) presented di-
chotomised data on number of patients ”improved or not im-
proved“. Few of the studies used specific scales to assess side ef-
fects. For this reason, we requested the individual patient data and
received this from eight out of ten included trials. This allowed an
analysis of the available data in a uniform way. However, even after
receiving individual patient data, adverse effects remained poorly
reported.
4.6.1 Outcome scales: details of the scales that provided useful
data are shown below. We have reported reasons for exclusion of
data under ’Outcomes’ in the ’Included studies’ table.
4.6.1.1 Global state
Clinical Global Impression - CGI (NIMH 1970)
A rating instrument commonly used in studies on schizophrenia
that enables clinicians to quantify severity of illness and overall
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clinical improvement during therapy. A seven-point scoring system
is usually used with low scores indicating decreased severity and/
or greater recovery.
4.6.1.2 Mental state
Brief Psychiatric Rating Scale - BPRS (Overall 1962)
A brief rating scale used to assess the severity of a range of psychi-
atric symptoms, including psychotic symptoms. The scale has 16
items, and each item can be defined on a seven-point scale varying
from ’not present’ (1) to ’extremely severe’ (7). Scoring goes from
24 -168.
Inpatient Multidimensional Rating Scale (Lorr 1962)
A rating scale used to assess the severity of a range of psychiatric
symptoms. Higher scores indicate more symptoms. We were un-
able to obtain further details.
Positive and Negative Symptom Scale - PANSS (Kay 1987)
This scale was developed to evaluate the positive, negative and gen-
eral symptoms in schizophrenia. The scale has 30 items, and each
item can be defined on a seven-point scoring system varying from
one (absent) to seven (extreme). This scale canbe divided into three
subscales for measuring the severity of general psychopathology,
positive symptoms (PANSS-P) and negative symptoms (PANSS-
N). Higher scores indicate more symptoms.
Scale for the Assessment of Negative Symptoms - SANS (
Andreasen 1982).
This six-point scale gives a global rating of the following negative
symptoms alogia, affective blunting, avolition-apathy, anhedonia-
asociality and attention impairment. Higher scores indicate more
symptoms.
Scale for the Assessment of Positive Symptoms - SAPS (Andreasen
1984)
This six-point scale gives a global rating of positive symptoms
such as delusions, hallucinations, and disordered thinking. Higher
scores indicate more symptoms.
Hamilton Rating Scale for Depression - HDRS (Hamilton 1960)
The instrument is designed to be used only on patients already
diagnosed as suffering from affective disorder of depressive type.
It is used for quantifying the results of an interview, and its value
depends entirely on the skill of the interviewer in eliciting the
necessary information. The scale contains 17 variables measured
on either a five-point or a three-point rating scale, the latter being
used where quantification of the variable is either difficult or im-
possible. Among the variables are: depressed mood, suicide, work
and loss of interest, retardation, agitation, gastro-intestinal symp-
toms, general somatic symptoms, hypochondriasis, loss of insight,
and loss of weight. It is useful to have two raters independently
scoring a patient at the same interview. The scores of the patient
are obtained by summing the scores of the two physicians.
Risk of bias in included studies
1. Randomisation
Six studies achieved an ’A’ category for randomisation concealment
(Heßlinger 1998, Nachshoni 1994, Carpenter 1991, Heßlinger
1998, Llorca 1993, Martin-Munoz 1989). All others studies were
allocated to the ’B’ quality score.
2. Blindness
All but two studies were double-blind (Heßlinger 1998, Mair
1990), although there was no description as to how blindness was
assured and never was it tested. In the methods section of this
review it was planned that only ratings carried out by independent
raters would be accepted. No study stuck to this rule. As data were
so sparse excluding further data would have not done a service to
the reader, this principle was no longer followed. There is little
danger of bias creeping in for this reason alone.
3. Loss to follow up
Only little data were given on patients who left the studies early.
4. Overall
Overall, the quality of the included trials varied, with the older
studies tending to use designs which would not be regarded as
excellent by modern research standards. Jadad scores of between
two (poor quality) and four (good quality) were reached by the
studies. Jadad score maximum is five.
Effects of interventions
1. The search
The original strategy identified hundreds of citations but only
10 studies met our inclusion criteria. In the update searches in
2005 and 2007 there were 24 and 23 new references respectively.
One report could be a further relevant randomised trial (Kamisada
1988), but due to insufficient information it had to be classified
as awaiting assessment. We have written to the first author. Five
references were further reports of studies that had been already
included or excluded in the first version of this review. They were
added as additional references. All other reports had to be excluded.
2. COMPARISON 01: CARBAMAZEPINE AS SOLE TREAT-
MENT versus PLACEBO AS SOLE TREATMENT
Only one trial Carpenter 1991compared carbamazepine as a sole
agent with placebo in maintenance treatment.
2.1 Leaving the study early
One person receiving carbamazepine left early due to a rash and
another due to leukopenia. Two people also left early from the
placebo group, due to a conduction defect on the ECG and
headache, respectively. No difference between groups was found
(1 RCT n=31, RR 1.1 CI 0.2 to 6.6).
2.2 Relapse
Data from the first 27 people included into this study showed that
carbamazepine was no more effective than placebo in preventing
relapse(1 RCT n=31, RR 1.1 CI 0.8 to 1.5). As the majority of
those in both groups (26 out of 31) did relapse, the study was
halted by three months.
2.3 Mental state
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There was no significant difference in terms of mental state as
measured by the number of patients with less than 20% BPRS
reduction (1 RCT n=31, RR 0.99 CI 0.8 to 1.3) or the mean
BPRS at endpoint between both groups (1 RCT n=27, WMD -
0.1 CI -0.5 to 0.3).
2.4 Adverse effects
Carpenter 1991 reported transient sedation and nausea in the car-
bamazepine group, although no figures were presented. Three peo-
ple treated with carbamazepine, this difference was not statistically
significant (1 RCT n=31, RR 7.4 CI 0.4 to 133) developed a rash
and one leukopenia, again differences between treatment groups
were not significant ( 1RCT n=31, RR 3.2 CI 0.1 to 73).
3. COMPARISON 02: CARBAMAZEPINE AS SOLE TREAT-
MENT versus ANTIPSYCHOTICS AS SOLE TREATMENT
Again, only one trial was found that compared carbamazepine
with perphenazine in acutely ill patients with schizophrenia and
schizoaffective disorder (Svestka 1989).
3.1 Leaving the study early
Two patients on carbamazepine versus none on perphenazine left
the study before its end, this difference is not statistically significant
(1 RCT n=38, RR 4.5 CI 0.2 to 88).
3.2 Mental state
No significant differences in terms of mental state were found.
A similar number of people treated with carbamazepine and per-
phenazine reached less than 20% (1RCT n=38, RR 1.3 CI 0.6 to
2.7), 35% (1RCT n=38, RR 1.7 CI 0.9 to 3.2) or 50% (1RCT
n=38, RR 1.2 CI 0.8 to 1.9) BPRS reduction. Again, no signif-
icant difference in terms of mean BPRS at endpoint was found
(1RCT n=38, WMD 2.3 CI -3.8 to 8.4). However, when those
with schizoaffective disorder were excluded, a statistically signifi-
cant inferiority of carbamazepine in terms of 20%BPRS reduction
(1RCT n=28, RR 3.1 CI 1.2 to 7.8, NNT 2 CI 1 to 6) and 35%
BPRS reduction (1RCT n=28, RR 2.3 CI 1.2 to 4.7, NNT 2 CI
1 to 7) was found. This effect was not as evident for 50% BPRS
reduction scores and the difference between groups just failed to
reach significance (1RCT n=28, RR 1.4 CI 0.9 to 2.1). Since only
ten participants had schizoaffective disorder, an analysis of this
subgroup was not thought to be meaningful.
3.3 Adverse effects
3.3.1 Movement disorders
Significantly more participants who received perphenazine needed
antiparkinson medication (1 RCT n=38, RR 0.2 CI 0.09 to 0.6,
NNH 1 CI 1 to 2) or had parkinsonism (1 RCT n=38, RR 0.03
CI 0.00 to 0.4, NNH 1 CI 0.9 to 1.4). No significant difference
in terms of number of participants with akathisia (1 RCT,n=38,
RR 0.1 CI 0.01 to 2.3) or tremor (1 RCT n=38, RR 0.3 CI 0.01
to 7.0) was found.
3.3.2 Other adverse effects
The following other adverse effects were reported: collapse, dizzi-
ness, blurred vision, dryness of mouth, fatigue, nausea, constipa-
tion, salivation, tachycardia. Studies found no significant differ-
ences between groups.
4. COMPARISON 03: ADJUNCTIVE CARBAMAZEPINE
+ ANTIPSYCHOTICS versus PLACEBO/NO ADJUNCTIVE
TREATMENT + ANTIPSYCHOTICS
Eight studies compared adding carbamazepine to antipsychotic
treatment with adding a placebo to antipsychotic treatment just
antipsychotic treatment alone.
4.1 Leaving the study early
Eight studies were able to contribute to the outcome of ’number
leaving the study early’, although four of these studies had no
one leave early in either group. No difference was found (8 RCTs
n=182, RR 0.5 CI 0.2 to 1.4) between those allocated to the
augmentation group and those taking placebo adjunctive therapy.
4.2 Global state
Only Neppe 1983 and Simhandl 1996 provided data on the out-
come ’no general improvement’. Carbamazepine augmentation
of neuroleptics was superior compared to various antipsychotics
alone, but the number of patients included was very low (2 RCTs
n=38, RR 0.6 CI 0.4 to 0.9, NNT 2, CI 1 to 5).
4.3 Mental state
4.3.1 General
The individual patient data from six studies could be used for the
analysis of various degrees of BPRS reduction. No significant dif-
ferences in terms of number of participants with less than 20% (6
RCTs n=147, RR 0.7 CI 0.4 to 1.1), 35% (6 RCTs n=147, RR
0.8 CI 0.6 to 1.1) or 50% BPRS reduction (6 RCTs n=147, RR
0.9 CI 0.7 to 1.1) were found. The results at the 50% BPRS re-
duction level were significantly heterogeneous because two studies
(Heßlinger 1998,Dose 1987) showed contrary results.Noobvious
reasons for this heterogeneity could be derived from the publica-
tions. Similar equivocal results were found when the mean BPRS
(3 RCTs n=79, WMD 0.3 CI -12.5 to 13.1) or IMPS at endpoint
(2 RCTs n=50, WMD 5.2 CI -11.1 to 21.4) were analysed.
4.3.2 Specific - positive symptoms, negative symptoms and de-
pression
Only very few data for specific symptoms of schizophrenia could
be extracted. In the Heßlinger 1998 study the participants of the
carbamazepine group had, on average, more positive symptoms at
endpoint than those in the control group (1 RCT n=18, WMD
4.2 CI 0.8 to 7.7). The Dose 1987 study showed oppositional
results, but the data could only be presented in the ’other data’ ta-
ble because they were skewed. No significant superiority of carba-
mazepine augmentation in terms of negative symptoms (2 RCTs
n=53, WMD -2.8 CI -6.7 to 1.2) or depression (1 RCT n=26,
WMD -0.4 CI -2.2 to 1.5) could be found.
4.4 Behaviour
Two studies presented data on the average dose of additional med-
ication needed for the treatment of agitated behaviour. In Dose
1987 people receiving carbamazepine augmentation needed less
additional medication, whereas in Heßlinger 1998 they needed
more additional medication than in the control group. Data were
skewed and could therefore only be presented in the other data
table.
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4.5 Adverse effects
Side effects were not well reported in the studies.
4.5.1 Movement disorders
The effect of adjunctive carbamazepine on movement disorders is
not clear. One small study (Martin-Munoz 1989) reported on the
binary outcome of ’movement disorder present’. Less people in
the carbamazepine augmentation group had movement disorders
than those taking haloperidol alone but the result just failed to
reach significance (1 RCT n=20, RR 0.4 CI 0.1 to 1.0). Skewed
data from the Simpson-Angus Scale were equivocal from three
studies (Dose 1987, Nachshoni 1994, Simhandl 1996).
Three studies (Dose 1987, Heßlinger 1998, Simhandl 1996) pre-
sented data on the mean dose of antiparkinson medication used.
These data are presented in the ’other data’ tables, because they
are skewed. No consistent trend can be derived from these data.
4.5.2 Other side effects
Two studies used scales in order to assess side-effects (Martin-
Munoz 1989, Mair 1990) but data were reported in such a way as
to be unusable for this review. Dose 1987 reported several carba-
mazepine-associated adverse effects (allergic reactions, elevation of
liver enzymes, leucopoenia, EEG change). Although these tended
to bemore prevalent in the carbamazepine augmented group, none
reached the level of statistical significance.
4.6 Physiological effects
Dose 1987 andHeßlinger 1998 describemean plasma haloperidol
to be lower in the carbamazepine-augmented groupbut again these
data are in the ’other data’ tables.
4.7 Missing outcomes
Carbamazepine is said to have an effect upon aggression. Neppe
1983 reports that overt aggression was rated twice as severe with
placebo compared to carbamazepine but no quantitative data were
reported. Llorca 1993 did not find between-group differences in
SAPS or BPRS hostility and aggressiveness items but only ’p’ values
were presented. No data were found for ’service’ outcomes such
as ’duration of hospital stay’. Nor were there data on satisfaction
with treatment or costs.
4.8 Schizophrenia sub-types
4.8.1 People with treatment resistant schizophrenia: Llorca 1993
examined the effectiveness of adjunctive carbamazepine in those
with treatment resistant schizophrenia (Kane 1988 criteria) using
a crossover design. No mental state data were directly reported (p-
values only) but carbamazepine was not stated to be better than
placebo in this small study (n=12). Simhandl 1996 also included
only those with schizophrenia who had fulfilled specific criteria
of neuroleptic non-response. Significantly more patients treated
with adjunctive carbamazepine improved according to the CGI
and reached at least 20% BPRS reduction. However, this result is
not consistent, because there was not significantly more patients
treated with carbamazepine augmentation than with placebo aug-
mentation reaching 35% and 50% BPRS reduction.
4.8.2 People with EEG abnormalities: Neppe 1983 examined a
small group of 13 relatively non-responsive patients with EEG
abnormalities of which nine had schizophrenia. In this crossover
trial, more patients fared somewhat better in the carbamazepine
than in the placebo phase for ’leaving the study earlier’, ’no global
clinical improvement’ and the mental state ratings (BPRS). The
patient populationwas quite heterogeneous and diagnostic criteria
were not indicated.
4.8.3 People with negative symptoms:Nachshoni 1994 carried out
a double blind randomised controlled trial in 28 residual patients
who were suffering predominantly from negative symptoms. After
5 weeks no superiority of adjunctive carbamazepine compared to
placebo on negative symptoms could be found.
4.8.4 People with schizoaffective disorder: Only 12 people in-
cluded in this review had schizoaffective disorder so analyses of
this subgroup did not appear to be meaningful.
D I S C U S S I O N
1. General
Although much original data were received from trialists, a total
of 258 participants is still a small base upon which to judge the
effectiveness of carbamazepine. Trials with small sample sizes lack
sufficient power to detect a small to moderate effect, and thus re-
sults from such trials are often inconclusive, even when a real effect
does exist. A recent review has suggested that meta-analyses based
on summation of small trials should be interpreted as inconclu-
sive, regardless of whether the combined estimate was significant
(Davey Smith 1998). The included studies in this review, were
therefore unable to provide sufficient data to clarify the role of car-
bamazepine for the treatment or augmentation of antipsychotic
treatment of schizophrenia and schizoaffective disorder.
2. COMPARISON 01. CARBAMAZEPINE AS SOLE TREAT-
MENT versus PLACEBO AS SOLE TREATMENT (Carpenter
1991)
The little available data suggest that carbamazepine is no better
than placebo formaintenance treatment. Considering that the sin-
gle study contributing data was stopped early, because the major-
ity of those in both groups relapsed, these data are unlikely to be
supplemented.
3. COMPARISON 02. CARBAMAZEPINE AS SOLE TREAT-
MENT versus ANTIPSYCHOTICS AS SOLE TREATMENT
(Svestka 1989)
In the only small study available, carbamazepine was not infe-
rior when compared with perphenazine in terms of improvement
of mental state and carbamazepine was associated with fewer ex-
trapyramidal side effects than perphenazine. However, due to the
small sample size of this trial (n=38) carbamazepine can not be
considered as a reasonable alternative to antipsychotics, and in
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the subgroup analysis in which those with schizoaffective disor-
der were excluded, perphenazine was superior to carbamazepine
in some efficacy outcomes.
4. COMPARISON 03. ADJUNCTIVE CARBAMAZEPINE
+ ANTIPSYCHOTICS versus PLACEBO/NO ADJUNCTIVE
TREATMENT + ANTIPSYCHOTICS
4.1 Leaving the study early
Only 13 out of 180 people left the studies before completion with
no difference between groups. This very low rate of attrition is
rare within trials relevant to the care of those with schizophrenia.
Adjunctive therapy of this sort seems to be very acceptable to
people with schizophrenia, at least within the confines of a trial.
4.2 General improvement
Two small trials (Neppe 1983, Simhandl 1996) presented data on
the outcome of ’no general improvement’, and found a slight, but
statistically significant difference between groups favouring the
carbamazepine group (NNT 2 CI 1-5). Little can be concluded
from two small trials including 38 schizophrenia patients. It is
disappointing that more trials did not report this simple outcome.
4.3 Mental state
The interpretation of results on mental state has been improved
by the analysis of individual patient data in a uniform way. The
meta-analysis of the data of six out of eight trials did not show a
significant superiority of carbamazepine according to several levels
of reduction of the Brief Psychiatric Rating Scale (Overall 1962).
Furthermore, there was a significant heterogeneity of the study
results with one study (Heßlinger 1998) showing especially bad
results associated with carbamazepine augmentation. The inspec-
tion of the methods of each study did not reveal clear reasons
for this heterogeneity. Therefore, current data suggests that car-
bamazepine augmentation of antipsychotic drugs for people with
schizophrenia does not seem to have a clinically meaningful effect
on mental state. However, since there was a non-significant trend
in terms of 20% BPRS reduction and since the total number of
patients is still low, more trials are warranted. Specific symptoms
of schizophrenia (positive symptoms, negative symptoms and de-
pression) were only reported by one or two trials so that any mean-
ingful statement was not possible.
4.4 Adverse effects
Most data aboutmovement disorders were too skewed to summate
and individual studies reported conflicting results. As a result, no
firm conclusion can be drawn. The fact that some studies found
that carbamazepine augmentation leads to fewer movement dis-
orders might be explained by a reduction of haloperidol plasma
levels. This lowering of plasma levels might be the expression of an
induction of liver enzymes related to carbamazepine. Two of the
included studies (Dose 1987, Heßlinger 1998), one trial excluded
because it did not provide any usable data (Kidron 1985), and
several uncontrolled trials (Kahn 1990, Jann 1985, Otani 1997)
suggest that this enzyme induction occurs. This interaction must
be carefully taken into account whenever carbamazepine augmen-
tation is tried.
Carbamazepine augmentation may well cause more allergic reac-
tions, elevation of liver enzymes, leucopoenia, and deterioration in
the EEG than placebo augmentation. Adverse effects were, how-
ever, poorly reported and the only small trial (Dose 1987, n=41)
that clearly reported these important events had limited power to
investigate differences between groups.
4.5 Missing outcomes
Currently, there are no data relating to the effect of carbamazepine
augmentation on aggression, ’service’ outcomes such as ’duration
of hospital stay’, satisfaction with treatment or costs.
4.6 Schizophrenia sub-types
Carbamazepine augmentation was not more effective when sub-
groups of people with schizophrenia were the focus of the stud-
ies. People with a schizophrenic illness designated as resistant to
treatment were not consistently better when they received carba-
mazepine augmentation. Those with negative symptoms were not
different in their response to antipsychotic augmentation com-
pared with people whose illness did not have a predominance of
negative symptoms. The small Neppe 1983 study (n=9) suggested
that a relatively non-responsive heterogeneous group of patients
with EEG abnormalities did fare somewhat better with carba-
mazepine augmentation than with placebo. This should be con-
sidered as hypothesis-generating only.
It is not clear whether it makes sense to use carbamazepine in
schizophrenia(-like) patients with ’excited states’. One randomised
controlled study (Klein 1984) suggested that this could be useful,
but data from this trial could not be used in this review as the
treatment allocation of people who left the study early is unclear.
In a letter the authors stated that they do not remember how to in-
terpret the data sheets of the study. Furthermore, a large controlled
study of adjunctive carbamazepine to antipsychotics in ’excited
psychoses’ (Okuma 1989a, n=162) had to be excluded because of
the potential for inclusion of bias at the point of randomisation.
Forty three percent of those in the carbamazepine augmentation
group showed marked and moderate improvement compared to
27% in the placebo group (not statistically significant). A post hoc
analysis of individual mental state scale items suggested that this
was related to an effect on disturbances of affective or emotional
functions, whereas other items like hallucinatory behaviour wors-
ened with adjunctive carbamazepine.
Finally, carbamazepine augmentation for those with schizoaffec-
tive disorder has been surprisingly poorly studied, although it is
frequently used in the daily routine for this condition. Only 12
participants included in this review had schizoaffective disorder so
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any judgment on the effects of carbamazepine for this important
subgroup are impossible.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
1. For clinicians
Based on currently available randomised trial-derived evidence,
carbamazepine cannot be recommended for routine clinical use
for treatment or augmentation of antipsychotic treatment of
schizophrenia. For patients with a past history of response to car-
bamazepine, a trial of the drug may be warranted. For health care
professionals currently caring for patients who have been receiv-
ing carbamazepine as a putative treatment for schizophrenia, clin-
icians need to weigh up whether this treatment should be stopped.
Carbamazepine is associated with a range of adverse effects. If
there is no evidence that the treatment has been effective, then
it should be gradually tapered off and then stopped altogether.
The dose of concomitant antipsychotics may need to be revised in
light of the potential pharmacokinetic interactions between carba-
mazepine and some antipsychotics as antipsychotic plasma levels
may rise upon withdrawal.
2. For people with schizophrenia
People with schizophrenia should know of the lack of a strong
empirical basis for the use of carbamazepine in their illness. If its
recommendation is still perused, the recipient of this treatment
should expect clear endpoints and duration of treatment to be
agreed upon.
3. For managers and policy makers
Although idiosyncratic positive responses are always possible, there
are no data to support the use of carbamazepine for those with
schizophrenia as a routine measure.
Implications for research
1. General
Any future studies should respect standards of measuring out-
comes and of reporting data in order to enhance the comparability
of study results (Begg 1996). The fact that several authors (see
acknowledgement) shared their data with us very much improved
the quality of this review. We would like to encourage similar col-
laboration in the future.
2. Specific
There seems to be little need to undertake randomised trials in-
vestigating the effects of carbamazepine augmentation for peo-
ple with uncomplicated schizophrenia. Some special indications
might, however, still be of research interest.
2.1 People whose illness is resistant to treatment
Despite the reintroduction of clozapine, the only drug proven to
have superior efficacy than standard drugs for those with treatment
resistant illness (Wahlbeck 1998), there is a need for the develop-
ment of treatment strategies when clozapine does not work. The
two randomised trials investigating the effects of carbamazepine
augmentation for people with treatment resistant schizophrenia
(Simhandl 1996, Llorca 1993) only randomised a total of 66 pa-
tients. Even the combined totals lack the power to identify any-
thing but gross differences between groups. Even small differences
in outcome may be of great importance in this sub-group and
therefore a large simple trial is justified.
2.2 People with psychoses and EEG abnormalities
Clarification of the role of carbamazepine for the treatment of
people with both schizophrenia and EEG abnormalities may be
warranted.
2.3 People with psychoses and aggressive behaviour
Carbamazepine is used for those with aggressive or violent episodes
and its evaluation within trials in this sub-group of people with
schizophrenia would be valuable.
2.4 People with schizoaffective disorders
Carbamazepine is also used for those with schizoaffective disorders
but data from placebo-controlled trials do not exist. The bipolar
type of schizoaffective disorder especially warrants further studies.
A C K N OW L E D G E M E N T S
We would like to thank very much Drs Carpenter, Svestka, Dose,
Neppe, Martin-Munoz, Simhandl, Normann and Nachshoni for
sending us their original patient data. Without their contribution
this update would not have been possible.
13Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
R E F E R E N C E S
References to studies included in this review
Carpenter 1991 {published data only}
Carpenter WT, Kurz R, Kirkpatrick B, Hanlon TE.
Carbamazepine maintenance treatment in outpatient
schizophrenics. Archives of General Psychiatry 1991;48(1):
69–72.
Dose 1987 {published data only}
Dose M. Die Bedeutung von Antikonvulsiva und
Calciumantagonisten für die Pharmakotherapie von Psychosen.
Habilitationsschrift. Technische Universität München,
1991.
Dose M, Apelt S, Emrich HM. Carbamazepine as an
adjunct of antipsychotic therapy. Psychiatry Research 1987;
22(4):303–10.
Dose M, Emrich HM. Carbamazepine as an adjunct to
antipsychotic treatment. Schizophrenia Research 1988;1(2,
3):207–8.
Dose M, Emrich HM. Combination of neuroleptics
with carbamazepine. Application in the treatment of
schizophrenic psychoses Combination of neuroleptics
with carbamazepine. Application in the treatment of
schizophrenic psychoses [Kombination von Neuroleptika
mit Carbamazepin. Einsatz in der Behandlung
schizophrener Psychosen]. Münchner Medizinische
Wochenschrift 1990;132 (suppl 1):87–90.
Dose M, Garcia D, Weber M, Yassouridis A, Emrich HM.
Combined treatment of schizophrenic psychoses with
neuroleptics and anticonvulsants. Pharmacopsychiatry 1989;
22(5):195.
Heßlinger 1998 {published and unpublished data}
Hesslinger B, Klose P, Normann C, Langosch JM, Berger M,
Walden J. Carbamazepine co-treatment in schizophrenia.
Fortschritte der Neurologie Psychiatrie 1998;66(4):145–50.
Hesslinger B, Normann C, Langosch JM, Klose P, Berger
M, Walden J. Effects of carbamazepine and valproate on
haloperidol plasma levels and on psychopathologic outcome
in schizophrenic patients. J Clin Psychopharmacol 1999;19
(4):310–5.
Normann C, Klose P, Hesslinger B, Langosch JM, Berger M,
Walden J. Haloperidol plasma levels and psychopathology
in schizophrenic patients with antiepileptic co-medication:
a clinical trial. Pharmacopsychiatry 1997;30:204.
Walden J, Hesslinger B, Normann C, Langosch J, Berger
M. Actions of carbamazepine and valproate on haloperidol
plasma levels and psychopathological outcome. Proceedings
of the 21st Congress of the Collegium Internationale
Neuro-psychopharmacologicum, Glasgow, Scotland. 1998.
Llorca 1993 {published data only}
Estorges JP, Llorca PM, Lancon C, Bougerol T, Scotto JC.
Carbamazepine as adjuvant treatment to neuroleptics in
schizophrenic patients. Encephale 1991;17(4):307.
Llorca PM, Wolf MA, Lancon C, Bougerol T.
Clinical efficacy of bromocriptine, carbamazepine,
and cyproheptadine as adjuvant to neuroleptics in 24
chronic resistant schizophrenics [Efficacite comparee de la
bromocriptine, de la carbamazepine et de la cyproheptadine
en association aux neuroleptiques chez 24 patients
schizophrenes chroniques resistants]. Encephale 1993;19(5):
565–71.
Mair 1990 {published data only}
Mair M, Tschapeller I, Schubert H. Kombinationstherapie
mit Neuroleptika und Carbamazepin. Eine kontrollierte
Studie.. In: Schonbeck G, Platz T editor(s). Schizophrenie
erkennen, verstehen, behandeln.Beiträge aus Theorie und
Praxis. Wien: Springer Verlag, 1990:77–92.
Martin-Munoz 1989 {published data only}
Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-
Martin I, Guajardo FI. La carbamacepina: un tratamiento
adjunto eficaz en las esquizofrenias. (Carbamazepine: An
effective adjunct treatment for schizophrenia.). Actas Luso
Espanolas de Neurologia, Psiquiatria y Ciencias Afines 1992;
20(1):11–6.
Martin-Munoz JC, Morinigo-Dominguez AV, Mateo-
Martin I, Ibarra IG. La carbamacepina: Un tratamiento
adjunto eficaz en las esquizofrenias. / Carbamazepine: An
efficacious adjuvant treatment in schizophrenia. Actas Luso
Espanolas de Neurologia, Psiquiatria y Ciencias Afines 1989;
17(4):245–50.
Nachshoni 1994 {published data only}
Nachshoni T, Levin Y, Levy A, Kritz A. A double-blind
trial of carbamazepine in negative symptom schizophrenia.
Biological Psychiatry 1994;35(1):22–6.
Neppe 1983 {published and unpublished data}
Neppe VM. Carbamazepine as adjunctive treatment in
nonepileptic chronic inpatients with EEG temporal lobe
abnormalities. Journal of Clinical Psychiatry 1983;44(9):
326–31.
Neppe VM. Carbamazepine in the psychiatric patient.
Lancet 1982;2(8293):334.
Neppe VM. Non-responsive psychosis - a biochemical
difference?. South African Medical Journal 1983;63(21):
797–8.
Simhandl 1996 {published data only}
Meszaros K, Simhandl C, Denk E, Liechtenstein A, Topitz
A, Thau K. A carbamazepine augmentation trial in chronic
nonresponsive schizophrenia. 1996;n/a:na/a.
Simhandl C, Meszaros K, Denk E, Thau K, Topitz
A. Adjunctive carbamazepine or lithium carbonate in
therapyresistant chronic schizophrenia [2]. Canadian
Journal of Psychiatry/ Revue Canadienne de Psychiatrie 1996;
41(5):317.
Svestka 1989 {published data only}
Svestka J, Ceskova E, Rysanek R, Nahunek K. Controlled
cross-over comparison of carbamazepine with perphenazine
in schizophrenic psychoses. Activitas Nervosa Superior 1989;
31(4):276–7.
References to studies excluded from this review
14Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Arana 1986 {published data only}
Arana GW. Does carbamazepine-induced reduction of
plasma haloperidol levels worsen psychotic symptoms?
138th Annual Meeting of the American Psychiatric
Association (1985, Dallas, Texas). American Journal of
Psychiatry 1986;143(5):650–1.
Azorin 1986 {published data only}
Azorin JM, Samuelian JC, Pringuey D, Donnet A. Place
de la carbamazepine dans le traitement des psychoses
endogenes: Resultats d’une etude ouverte. / Place of
carbamazepine in the treatment of endogenous psychoses:
Results of an open trial. Encephale 1986;12(3):115–9.
Ballenger 1984 {published data only}
Ballenger JC, Post RM. Carbamazepine in alcohol and
withdrawal syndromes and schizophrenic psychoses.
Psychopharmacology Bulletin 1984;20:572–584.
Barnes 1996 {published data only}
Barnes TR, McEvedy CJ. Pharmacological treatment
strategies in the non-responsive schizophrenic patient.
International Clinical Psychopharmacology 1996;11(s2):
67–71.
Bellaire 1990 {published data only}
Bellaire W, Demisch K, Stoll K-D. Carbamazepine vs.
lithium. Application in the prophylaxis of recidivating
affective and schizoaffective psychoses Carbamazepine vs.
lithium. Application in the prophylaxis of recidivating
affective and schizoaffective psychoses [Carbamazepin
vs. Lithium. Einsatz in der Prophylaxe rezidivierender
affektiver und schizoaffektiver Psychosen]. Münchner
Medizinische Wochenschrift 1990;132:82–6.
Birkheimer 1985 {published data only}
Birkhimer LJ, Curtis JL, Jann MW. Use of carbamazepine
in psychiatric disorders. Clinical Pharmacology 1985;4(4):
425–34.
Borison 1991 {published data only}
Borison RL, Diamond BI, Dren AT. Does sigma receptor
antagonism predict clinical antipsychotic efficacy?
. Psychopharmacology Bulletin 1991;27(2):103–6.
[MEDLINE: 92021349; : PMID 1681560]
Botte 1988 {published data only}
Botte L, Charles G. Utilisations cliniques de la
carbamazepine: Revue de la litterature et resultats
personnels. / Clinical use of carbamazepine: Review from
the literature and personal results. Acta Psychiatrica Belgica
1988;88(3):181–94.
Cabrera 1987 {published data only}
Cabrera J, Albrecht J, Muller-Oerlinghausen B. Combined
preventive treatment of recurrent manic-depressive
disease with lithium and carbamazepine or oxcarbazepine.
Nervenarzt 1987;58(4):245–9.
Cegalis 1984 {published data only}
Cegalis JA, Possick SG. Carbamazepine and psychotherapy
in the treatment of schizoaffective psychosis. Yale Journal of
Biology and Medicine 1985;58(4):327–36.
Chouinard 1990 {published data only}
Chouinard G, Sultan S. Treatment of supersensitivity
psychosis with antiepileptic drugs: Report of a series of 43
cases. Psychopharmacology Bulletin 1990;26(3):337.
Costa 1986 {published data only}
Costa JF, Sramek J, Herrera JM. Hepatic reaction to
carbamazepine. Journal of Clinical Psychopharmacology
1986;6(4):251–2.
Covell 2004 {published data only}
Covell NH, Weissman EM, Essock SM. Weight gain
with clozapine compared to first generation antipsychotic
medications. Schizophrenia Bulletin 2004;30(2):229–40.
[MEDLINE: 15279042; : EMBASE 2004274059]
Dalby 1971 {published data only}
Dalby MA. Antiepileptic and psychotropic effect of
carbamazepine (Tegretol) in the treatment of psychomotor
epilepsy. Epilepsia 1971;12(12):335–40.
de Vogelaer 1981 {published data only}
de Vogelaer J. Carbamazepine in the treatment of psychotic
and behavioral disorders. A pilot study. Acta psychiatrica
belgica 1981;81:532–541.
Dehing 1968 {published data only}
Dehing J. Studies on the psychotropic action of tegretol.
Acta Neurologica Belgica 1968;68:895–905.
Denicoff 1994 {published data only}
Denicoff KD, Meglathery SB, Post RM, Tandeciarz SI.
Efficacy of carbamazepine compared with other agents: A
clinical practice survey. Journal of Clinical Psychiatry 1994;
55(2):70.
Elphick 1985 {published data only}
Elphick M. An open clinical trial of carbamazepine in
treatment-resistant bipolar and schizo-affective psychotics.
British Journal of Psychiatry 1985;147:198–200.
Frankenburg 1988 {published data only}
Frankenburg FR, Tohen M, Cohen BM, Lipinski JF. Long-
term response to carbamazepine: A retrospective study.
Journal of Clinical Psychopharmacology 1988;8(2):130–2.
Gadow 1992 {published data only}
Gadow KD. Pediatric psychopharmacotherapy: A review of
recent research. Journal of Child Psychology and Psychiatry
and Allied Disciplines 1992;33(1):153–95.
Galletly 1997 {published data only}
Galletly CA, Tsourtos G. Antipsychotic drug doses
and adjunctive drugs in the outpatient treatment of
schizophrenia. Annals of Clinical Psychiatry 1997;9(2):
77–80.
Ginestet 1996 {published data only}
Ginestet D, Ghanem T, Slama M. The variety of indications
for carbamazepine. Revue du Praticien Medecine Generale
1996;10(336):11.
Goncalves 1985 {published data only}
Goncalves N, Stoll KD. A controlled double-blind trial
of carbamazepine in manic illness [Carbamazepin bei
manischen Syndromen. Eine kontrollierte Doppelblind–
Studie]. Nervenarzt 1985;56(1):43–7.
15Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Greil 1997 {published data only}
Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR.
Lithium vs cambamazepine in the maintenance treatment
of schizoaffective disorder: A randomised study. European
Archives of Psychiatry and Clinical Neuroscience 1997;247(1):
42–50.
Hakola 1982 {published data only}
Hakola HA, Laulumaa VA. Carbamazepine in treatment of
violent schizophrenics. Lancet 1982;1(8285):1358.
Hermle 1993 {published data only}
Hermle L, Spitzer M. Succesful desensitization of a patient
with schizoaffective psychosis and carbamazepin allergy.
Nervenarzt 1993;64(3):208.
Herrera 1987 {published data only}
Heh CW, Sramek J, Herrera J, Costa J. Exacerbation of
psychosis after discontinuation of carbamazepine treatment.
American Journal of Psychiatry 1988;145(7):878–9.
Herrera JM, Sramek JJ, Costa JF. Efficacy of adjunctive
carbamazepine in the treatment of chronic schizophrenia.
Drug Intell Clin Pharm 1987;21(4):355–8.
Iwahashi 1995 {published data only}
Iwahashi K, Miyatake R, Suwaki H, Hosokawa K. The
drug-drug interaction effects of haloperidol on plasma
carbamazepine levels. Clinical Neuropharmacology 1995;18
(3):233–6.
Iwahashi 1996 {published data only}
Iwahashi K. Significantly higher plasma haloperidol level
during cotreatment with carbamazepine may herald cardiac
change [see comments]. Clinical Neuropharmacology 1996;
19(3):267–70.
Jann 1985 {published data only}
Jann MW, Ereshefsky L, Saklad SR, Seidel DR, Davis CM,
Burch NR, Bowden CL. Effects of carbamazepine on plasma
haloperidol levels. Journal of Clinical Psychopharmacology
1985;5(2):106–9.
Johns 1995 {published data only}
Johns CA, Thompson JW. Adjunctive treatments in
schizophrenia: Pharmacotherapies and electroconvulsive
therapy. Schizophrenia Bulletin 1995;21(4):607–19.
Kahn 1990 {published data only}
∗ Kahn EM, Schulz SC, Perel JM, Alexander JE. Change
in haloperidol level due to carbamazepine: A complicating
factor in combined medication for schizophrenia. Journal of
Clinical Psychopharmacology 1990;10(1):54–7.
Karper 1992 {published data only}
Karper LP, Seibyl JP, Krystal JH. Valproate management
of psychosis in a patient with carbamazepine-induced
hyponatremia. Journal of Clinical Psychopharmacology 1992;
12(2):137–9.
Keck 1996 {published data only}
Keck PE, McElroy SL, Strakowski SM. New developments
in the pharmacologic treatment of schizoaffective disorder.
Journal of Clinical Psychiatry 1996;57(s9):41–8.
Kessler 1989 {published data only}
Kessler AJ, Barklage NE, Jefferson JW. Mood disorders
in the psychoneurologic borderland: Three cases of
responsiveness to carbamazepine. 29th Annual Meeting
of the International Psychiatric Research Society (1987,
Madison, Wisconsin). American Journal of Psychiatry 1989;
146(1):81–3.
Kidron 1985 {published data only}
Kidron R, Averbuch I, Klein E, Belmaker RH.
Carbamazepine-induced reduction of blood levels of
haloperidol in chronic schizophrenia. Biological Psychiatry
1985;20(2):219–22.
Klein 1984 {published data only}
Klein E, Bental E, Lerer B, Belmaker RH. Carbamazepine
and haloperidol v placebo and haloperidol in excited
psychoses. A controlled study. Archives of General Psychiatry
1984;41(2):165–70.
Kraft 1984 {published data only}
Kraft AM, Hassenfeld IN, Zarr M. Response to functional
hallucinations to carbamazepine. American Journal of
Psychiatry 1984;141(8):1018.
Lambert 1987 {published data only}
Lambert PA, Venaud G. Use of valpromide in psychiatric
therapeutics.. Encephale 1987;13(6):367–73. [:
CN–00477270]
Lapensee 1992 {published data only}
Lapensee MA. A review of schizoaffective disorder: II.
Somatic treatment. Canadian Journal of Psychiatry Revue
Canadienne de Psychiatrie 1992;37(5):347.
Lenzi 1986 {published data only}
Lenzi A, Lazzerini F, Grossi E, et al.Use of carbamazepine in
acute psychosis: A controlled study. Journal of International
Medical Research 1986;14(2):78–84.
Llorca 1992 {published data only}
Llorca PM, Wolf MA, Lancon C, Bougerol T. Adjuvant
drugs for use in patients under neuroleptics. Annales de
Psychiatrie 1992;7(4):195.
Luchins 1983 {published data only}
Luchins DJ. Carbamazepine for the violent psychiatric
patient. Lancet 1983;1(8327):766.
Luchins DJ. Carbamazepine in violent nonepileptic
schizophrenics. Psychopharmacology Bulletin 1984;20(3):
569–571.
Luchins 1984 {published data only}
Luchins DJ. Fatal agranulocytosis in a chronic schizophrenic
patient treated with carbamazepine. American Journal of
Psychiatry 1984;141(5):687–8.
Makaric 2000 {published data only}
Makaric G, Folnegovic-Smalc V, Folnegovic Z, Imica N.
Agitation in acute episode of schizophrenia: carbamazepine
treatment in combination with haloperidol versus combined
neuroleptics. Schizophrenia Research 2000;41(1):210.
[MEDLINE: 1999367069]
16Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
McAllister 1985 {published data only}
McAllister TW. Carbamazepine in mixed frontal lobe and
psychiatric disorders. Journal of Clinical Psychiatry 1985;46
(9):393–4.
McKee 1989 {published data only}
McKee RW, Larkin JG, Brodie MJ. Acute psychosis with
carbamazepine and sodium valproate. Lancet 1989;1(8630):
167.
Meltzer 1992 {published data only}
Meltzer HY. Novel approaches to the pharmacotherapy
of schizophrenia. Drug Development Research 1986;9(1):
23–40.
Meltzer HY. Treatment of the neuroleptic-nonresponsive
schizophrenic patient. Schizophrenia Bulletin 1992;18(3):
515–42.
Meshel 1967 {published data only}
Meshel E, Denber HC. Double-blind study of tybamate in
psychotic patients. Diseases of the Nervous System 1967;28
(5):311–3. [MEDLINE: 67165839; : PMID 5338174]
Meshel 1968 {published data only}
Meshel E, Denber HC. The use of tybamate in psychotic
patients. (A further double blind study). Diseases of
the Nervous System 1968;29(4):243–5. [MEDLINE:
68271597; : PMID 4870945]
Miceli 2000 {published data only}
∗ Miceli JJ, Anziano RJ, Robarge L, Hansen RA, Laurent
A. The effect of carbamazepine on the steady-state
pharmacokinetics of ziprasidone in healthy volunteers.
British Journal of Clinical Pharmacology 2000;49 (suppl I):
65S–70S.
Miller 1965 {published data only}
Miller MJ, Shettel R, Fiedler HT. Chronic toxicologic
evaluation of hydroxyphenamate and possible synergism
with phenothiazines. Psychosomatics 1965;6(5):340–2.
[MEDLINE: 66013834; : PMID 5319246]
Miodownik 2003 {published data only}
Miodownik C, Cohen H, Kotler M, Lerner V. Vitamin B6
add-on therapy in treatment of schizophrenic patients with
psychotic symptoms and movement disorders. Harefuah
2003;142(8-9):592-6, 647. [MEDLINE: 14518160; :
EMBASE 2003374828; CN–00440574.]
Mokrusch 1987 {published data only}
Mokrusch T, Negele J, Kaschka WP. New aspects in the
prophylaxis of affective and schizoaffective psychoses.
Fortschritte der Medizin 1987;105(1):30–4.
Morinigo 1992 {published data only}
Morinigo A, Mateo I, Martin J, Noval D, Gonzalez S.
Efectos terapeuticos del valproato sodico y la carbamacepina
en la mania. Psiquis 1992;13(8):335–8.
Mosca 1998 {published data only}
Mosca LD//Licciardo JP//Coppola JL. A double-blind
carbamazepine-controlled efficacy and safety study of
valproate in impulsivity and violence. 11th Congress of The
European College of Neuropsychopharmacology; Oct 31 -
Nov 4, Paris, France. 1998. [MEDLINE: CONFERENCE
ABSTRACT]
Munetz 1989 {published data only}
Munetz MR, Schulz SC, Bellin M, Harty I. Rimcazole
(BW234U) in the maintenance treatment of outpatients
with schizophrenia. Drug Development Research 1989;16(1):
79–83. [MEDLINE: 83197879; : PMID 6342171]
Möller 1989 {published data only}
Moller HJ, Kissling W, Riehl T, Bauml J. Double-
blind evaluation of the antimanic properties of
carbamazepine as a comedication to haloperidol. Progress in
Neuropsychopharmacology and Biological Psychiatry 1989;13
(1-2):127–36.
Möller 1996 {published data only}
Moller H. Treatment of schizophrenia. State of the art.
European Archives of Psychiatry and Clinical Neuroscience
1996;246(5):229.
Nasser 1990 {published data only}
Nasser D, Thomas B. Anticonvulsant treatment of
psychoses. Australian and New Zealand Journal of Psychiatry
1990;24(2):164.
Nelson 1993 {published data only}
Nelson JC. Combined treatment strategies in psychiatry.
Journal of Clinical Psychiatry 1993;54(s9):42.
Neppe 1988a {published data only}
Neppe VM. Carbamazepine in nonresponsive psychosis.
Journal of Clinical Psychiatry 1988;49(s):22–8.
Neppe 1988b {published data only}
Neppe VM, Tucker GJ, Wilensky AJ. Fundamentals of
carbamazepine use in neuropsychiatry. Journal of Clinical
Psychiatry 1988;49(s):4–6.
Neppe 1988c {published data only}
Neppe VM. Carbamazepine for withdrawal
pseudohallucinations. American Journal of Psychiatry 1988;
145(12):1605.
Neppe 1991 {published data only}
Neppe VM, Bowman BR, Sawchuk KS. Carbamazepine for
atypical psychosis with episodic hostility. Journal of Nervous
and Mental Disease 1991;179(7):439–41.
Nijdam 1992 {published data only}
Nijdam JR, Doorschot CH, van Bavel LP, Loonen
AJ. A comparison of carbamazepine Divitabs and a
normal carbamazepine preparation in psychiatric and
oligophrenic patients. Pharmacopsychiatry 1992;25(3):
145–9. [MEDLINE: 92342659]
Okuma 1989a {published and unpublished data}
Okuma T, Yamashita I, Takahashi R, Itoh H. A double-
blind study of adjunctive carbamazepine versus placebo on
excited states of schizophrenic and schizoaffective disorders.
Acta Psychiatrica Scandinavica 1989;80(3):250–9.
Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S,
Watanabe S, Sarai K, Ozama H, Inanaga K. Comparison
of the therapeutic effect of carbamazepine and placebo
in schizophrenia and atypical psychosis by double blind
controlled study. Rinsho Hyoka 1988;16(2):327–73.
17Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Okuma 1989b {published data only}
Okuma T, Yamashita I, Takahashi R, Itoh H. Clinical
efficacy of carbamazepine in affective, schizoaffective, and
schizophrenic disorders. Pharmacopsychiatry 1989;22(2):
47–53.
Ortega 1991 {published data only}
Hernandez-Avila CA, Ortega-Soto HA, Jasso A, Hasfura-
Buenaga CA, Kranzler HR. Treatment of inhalant-induced
psychotic disorder with carbamazepine versus haloperidol.
Psychiatric Services 1998;49:812–15.
Ortega SHA, Jasso A, Cecena G, Hernandez ACA. Validity
and reproductivity of a scale for measuring neuroleptic-
induced extrapyramidal symptoms [La validez y la
reproducibilidad de dos escalas para evaluar los sintomas
extrapiramidales inducidos por neurolepticos]. Salud
Mental 1991;14(3):1–5.
Otani 1997 {published data only}
Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki
A, Furukori H, Kaneko S, Inoue Y. Interaction between
carbamazepine and bromperidol. European Journal of
Clinical Pharmacology 1997;52(3):219.
Pantelis 1996 {published data only}
Pantelis C, Barnes TR. Drug strategies and treatment-
resistant schizophrenia. Australian and New Zealand Journal
of Psychiatry 1996;30(1):20–37.
Panu 1984 {published data only}
Panu H, Hakola A, Laulumaa VA. Carbamazepine in violent
schizophrenics. In: Emrich HM, Okuma T editor(s).
Anticonvulsants in affective disorders. Amsterdam: Elsevier,
1984:204–7.
Placidi 1986 {published data only}
Placidi GF, Lenzi A, Lazzerini F, Cassano GB. The
comparative efficacy and safety of carbamazepine versus
lithium: A randomized, double-blind 3-year trial in 83
patients. Journal of Clinical Psychiatry 1986;47(10):490–4.
Placidi GF, Lenzi A, Rampello E, Andreani MF, Cassano
GB, Grossi E. Long term-double blind prospective study on
carbamazepine versus lithium in bipolar and schizoaffective
disorders. Preliminary results.. In: Emrich HM, Okuma T
editor(s). Anticonvulsants in affective disorders. Amsterdam:
Elsevier, 1984:188–97.
Raitasuo 1994 {published data only}
Raitasuo V, Lehtovaara R, Huttunen MO. Effect of
switching carbamazepine to oxcarbazepine on the plasma
levels of neuroleptics: A case report. Psychopharmacology
1994;116(1):115–6.
Rankel 1988 {published data only}
Rankel HW, Rankel LE. Carbamazepine in the treatment
of catatonia. American Journal of Psychiatry 1988;145(3):
361–2.
Rittmannsberger 1990 {published data only}
Rittmannsberger H. Carbamazepine in the treatment
of psychiatric illness: Effects and side effects. Wiener
Medizinische Wochenschrift 1990;140(15):398.
Scher 1983 {published data only}
Scher M, Neppe V. Carbamazepine adjunct for
nonresponsive psychosis with prior hallucinogenic abuse.
Journal of Nervous and Mental Disease 1989;177(12):755.
Schulz 1990 {published data only}
Schulz SC, Conley RR, Kahn EM, et al.Nonresponders to
neuroleptics: a distinct subtype. Schizophrenia: scientific
progress. New York: Oxford University Press, Date of
publication and page numbers not indicated.
Schulz SC, Kahn EM, Baker RW, et al.Lithium and
carbamazepine augmentation in treatment-refractory
schizophrenia. The neuroleptic-nonresponsive patient:
Characterization and treatment. Washington DC: American
Psychiatric Press, 1990:111–36.
Simhandl 1992 {published data only}
Simhandl C, Meszaros K. The use of carbamazepine in the
treatment of schizophrenic and schizoaffective psychoses: A
review. Journal of Psychiatry and Neuroscience 1992;17(1):
1–14.
Siris 1993 {published data only}
Siris SG. Adjunctive medication in the maintenance
treatment of schizophrenia and its conceptual implications.
British Journal of Psychiatry 1993;163(s22):22–78.
Sramek 1988 {published data only}
Heh CW, Potkin SG, Pickar D, Costa J, Herrera J, Sramek
J, DeMet E. Serum homovanillic acid concentrations in
carbamazepine-treated chronic schizophrenics. Biological
Psychiatry 1989;25(5):639–41.
Herrera J, Sramek J, Costa C, Heh C, Wernberg C.
An evaluation of carbamazepine (Tegretol) in chronic
treatment-refractory schizophrenia. Proceedings of the 95th
Annual Conference of the American Psychiatric Association.
1987:588–9.
Sramek J, Herrera J, Costa J, Heh C, Tran Johnson T,
Simpson G. A carbamazepine trial in chronic, treatment-
refractory schizophrenia. American Journal of Psychiatry
1988;145(6):748–50.
Tran-Johnson T, Sramek JJ, Walker NR, Heh CD, Costa JF,
Herrera JM. Effects of carbamazepine on serum calcium in
schizophrenia. DICP 1989;23(12):1034.
Sugerman 1970 {published data only}
Sugerman AA, Hyams L. Electroencephalographic
effects of adrenochrome semicarbazone in schizophrenia:
quantitative amplitude analysis. Research Communications
in Chemical Pathology and Pharmacology 1970;1(1):86–98.
[MEDLINE: 72091267; : PMID 4944698]
Svestka 1985 {published data only}
Svestka J, Nahunek K, Ceskova E, Korbicka J.
Carbamazepine prophylaxis of affective psychoses:
Intraindividual comparison with lithium carbonate. 27th
Annual Psychopharmacology Meeting (1985, Jesenik,
Czechoslovakia). Activitas Nervosa Superior 1985;27(4):
261–2.
Svestka 1988 {published data only}
Svestka J, Nahunek K, Ceskova E. Pouziti carbamazepinu
v lecbe a profylaxi afektivnich psychoz. / Carbamazepine
18Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in the treatment and prophylaxis of affective psychoses.
Ceskoslovenska Psychiatrie 1988;84(3):145–55.
Tohen 1994 {published data only}
Tohen M, Castillo J, Pope HG, Herbstein J. Concomitant
use of valproate and carbamazepine in bipolar
and schizoaffective disorders. Journal of Clinical
Psychopharmacology 1994;14(1):67.
Walden 1996 {published data only}
Walden J, Von WJ, Berger M, Grunze H. Efficacy of
antiepileptic drugs in the treatment of psychiatric diseases.
EEG Labor 1996;18(1):32.
Wetterling 1987 {published data only}
Wetterling T. Open clinical trial of carbamazepine in
chronic schizophrenic inpatients. Pharmacopsychiatry 1987;
20(3):127–30.
Wunderlich 1983 {published data only}
Wunderlich HP, Grunes JU, Neumann J, Zahlten W.
Carbamazepine (Finlepsin(TM)) for manicdepressive and
schizophrenic diseases. Deutsche Gesundheitswesen 1983;38
(35):1352–6.
Yassa 1983 {published data only}
Yassa R, Dupont D. Carbamazepine in the treatment of
aggressive behavior in schizophrenic patients: A case report.
Canadian Journal of Psychiatry 1983;28(7):566–8.
References to studies awaiting assessment
Kamisada 1988 {published data only}
Kamisada M, Tateyama M, Nakano Y, Kawachi Y, Fujii Y,
Tanoue A, Takamiya M, Nakajima S, Sakuma K, Oguchi
E, Yagi G. Comparison of the Clinical Effects of Lithium
Carbonate and Carbamazepine on Excited Schizophrenics.
Psychopharmacology 1988;96(Suppl):348. [MEDLINE:
72091267; : PMID 4944698]
Lee 1996 {published data only}
Lee MS, Choi BH, Kim SH. Combined use of
carbamazepine and valproic acid in negative symptom
schizophrenia. 9th Congress of the European College of
Neuropsychopharmacology; September 21-25, Amsterdam,
The Netherlands. 1996. [MEDLINE: 98249354]
Additional references
Ahonen 1998
Ahonen J, Cheine M, Wahlbeck K. Supplementing
standard drug treatment of those with schizophrenia with
beta-blocking medication (Cochrane Review).. Cochrane
Database of Systematic Reviews 1998, Issue Issue 2.
Altman 1996
Altman DG, Bland JM. Detecting skewness from summary
information. BMJ 1996;313:1200.
Andreasen 1982
Andreasen NC. Negative symptoms in schizophrenia:
definition and reliability. Archives of General Psychiatry
1982;39:784–8.
Andreasen 1984
Andreasen NC. The scale for assessment of positive
symptoms. University of Iowa 1984.
Begg 1996
Beg C, Cho M, Eastwood S, Horton R, Moher D, Olkin
I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF.
Improving the quality of reporting of randomized controlled
trials: the CONSORT statement. JAMA 1996;276:637–9.
Bland 1997
Bland JM, Kerry SM. Statistics notes. Trials randomised in
clusters. BMJ 1997;315:600.
Boissel 1999
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F,
Buyse M, Boutitie F, Nony P, Haugh M, Mignot G. The
problem of therapeutic efficacy indices. 3. Comparison of
the indices and their use. Therapie 1999;54(4):405–11.
Christison 1991
Christison GW, Kirch DG, Wyatt RJ. When symptoms
persist: choosing among alternative somatic treatments for
schizophrenia. Schizophrenia Bulletin 1991;17:217–45.
Dardennes 1995
Dardennes R, Even C, Bange F, Heim A. Comparison of
carbamazepine and lithium in the prophylaxis of bipolar
disorder: a meta-analysis. British Journal of Psychiatry 1995;
166:378–81.
Davey Smith 1998
Davey Smith G, Egger M. Meta-analysis: Unresolved issues
and future developments. BMJ 1998;16:221–5.
Deeks 2000
Deeks J. Issues in the selection for meta-analyses of binary
data. Abstracts of 8th International Cochrane Colloquium;
2000 Oct 25-28th; Cape Town, South Africa. 2000.
Divine 1992
Divine GW, Brown JT, Frazer LM. The unit of analysis
error in studies about physicians’ patient care behavior.
Journal of General Internal Medicine 1992;7:623–9.
Donner 2002
Donner A, Klar N. Issues in the meta-analysis of cluster
randomized trials. Statistics in Medicine 2002;21:2971–80.
Egger 1997
Egger M, Davey mith G, Schneider M, Minder C. Bias in
meta-analysis detected by a simple, graphical test. BMJ
1997;315:629–34.
Gulliford 1999
Gulliford MC, Ukoumunne OC, Chinn S. Components
of variance and intraclass correlations for the design of
community-based surveys and intervention studies: data
from the Health Survey for England 1994. American Journal
of Epidemiology 1999;149:876–83.
Hamilton 1960
Hamilton M. A rating scale of depression. Journal of
Neurology, Neurosurgery and Psychiatry 1960;23:56–62.
19Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Higgins 2005
Higgins JPT, Green S. Cochrane Handbook for Systematic
Reviews of Interventions 4.2.5. Cochrane Database of
Systematic Reviews 2005, Issue 3.
Jadad 1996
Jadad A, Moore A, Carroll D, Jenkinson C, Reynolds
DJM, Gavanagh DJ, McQuay HJ. Assessing the quality of
reports of randomized clinical trials: Is blinding necessary?.
Controlled Clinical Trials 1996;17:1–12.
Kane 1988
Kane JM,Honigfeld G, Singer J, Meltzer H, and the Clozaril
Collaborative study group. Clozapine for the treatment-
resistant schizophrenic. A double-blind comparison with
chlorpromazine. Archives of General Psychiatry 1988;45:
789–96.
Kay 1987
Kay SR, Fiszbein A. The positive and negative symptome
scale (PANSS) for schizophrenia. Schizophrenia Bulletin
1987;13(2):261–75.
Lorr 1962
Lorr M, McNair DM, Klett CJ, Lasky JJ. Evidence of ten
psychotic symptoms. Journal of Consulting Psychology 1962;
26:185.
NIMH 1970
Clinical global impression. Manual for the ECDEU
Assessment Battery. 2nd. Washington DC, USA: National
Institute of Mental Health, 1970.
Overall 1962
Overall JE, Gorham DR. The brief psychiatric rating scale.
Psychological Reports 1962;10:790–812.
Schooler 1993
Schooler NR, Keith SJ. Clinical research for the treatment
of schizophrenia. Psychopharmacology Bulletin 1993;29:
431–46.
Schulz 1995
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical
evidence of bias: dimensions of methodological quality
associated with estimates of treatment effects in controlled
trials. JAMA 1995;273:408–12.
Tharyan 2002
Tharyan P. Electroconvulsive therapy for schizophrenia
(Cochrane Review). Cochrane Database of Systematic Reviews
2002, Issue 1.
Tiihonen 1995
Tiihonen J, Vartiainen H, Hakola P. Carbamazepine-
induced changes in plasma levels of neuroleptics.
Pharmacopsychiatry 1995;28:26–8.
Ukoumunne 1999
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC,
Burney PGJ. Methods for evaluating area-wide and
organisation-based interventions in health and health care:
a systematic review. Health Technology Assessment 1999;3(5):
iii–92. [MEDLINE: 10982317]
Wahlbeck 1998
Wahlbeck K, Cheine M, Essali MA, Rezk E. Clozapine
vs ’typical’ neuroleptic medication for schizophrenia
(Cochrane Review). Cochrane Database of Systematic Reviews
1998, Issue 2.
References to other published versions of this review
Leucht 2002
Leucht S, McGrath J, White P, Kissling W. Carbamazepine
augmentation for schizophrenia: how good is the evidence?.
Journal of Clinical Psychiatry 2002;63(3):218–24.
∗ Indicates the major publication for the study
20Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Carpenter 1991
Methods Allocation: randomised - no further details.
Blinding: double - no further information.
Design: cross-over.
Duration: 95 days each phase.
Setting: outpatient department.
Participants Diagnosis: schizophrenia (DSM-III & RDC).
N=34.*
Sex: 18 M, 9 F.*
Age: mean ~ 33 years.
History: stabilised on neuroleptic maintenance, hospitalised ~3 times, ill ~10 years
Interventions 1. Carbamazepine: dose 800-1200 mg/day. N~15.*
2. Placebo (neuroleptics withdrawn over 1-5 days when study medication dose was reached). N~16.*
Outcomes 1. Leaving the study early.
2. Relapse.*
3. Mental state: BPRS (mean and number with 20% reduction).*
4. Side effects - allergic reactions, blood dyscrasia.*
Notes Data analysed on 31 patients, no information about treatment status of 3 people.
Jadad score = 4.
Interim analyses showed high relapse rates in both arms of study - study stopped
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Dose 1987
Methods Allocation: randomised - no further details.
Blinding: double - no further information.
Design: parallel.
Duration: 5 weeks (at week 4 interventions withdrawn).
Setting: in hospital.
Participants Diagnosis: acute schizophrenia (ICD-9 & DSM-III).
N=41.
Sex: not reported.
Age: not reported.
History: hospitalised ~1.2 times, ill ~6 years.
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Dose 1987 (Continued)
Interventions 1. Adjunctive carbamazepine: dose 200mg, increased to 600-1200mg/day (target plasma level 8-12 mi-
crograms/dL) + haloperidol 6mg/day then titrated to clinical judgement. N=18.
2. Placebo additional treatment + haloperidol 6mg/day then titrated to clinical judgement. N=23
Outcomes 1. Leaving the study early
2. Mental state: (BPRS 20%, 35%, 50% reduction, mean at endpoint; mean IMPS at endpoint).
3. Side-effects: allergic reactions, substantial white blood cell decline, increase of liver enzymes, worsening
of EEG
Unable to use:
Medication use (mean haloperidol dose - no SD, biperiden, chlorprothixene - data skewed).
Movement disorder (SAS - data skewed).
Haloperidol plasma-levels - data skewed.
Notes Jadad score = 4.
** Two people taking carbamazepine had falls in white cell counts, but not below usual reference range
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Heßlinger 1998
Methods Allocation: randomised - sealed envelopes.
Blinding: single.
Design: parallel.
Duration: 4 weeks.
Setting: in hospital.
Participants Diagnosis: schizophrenia (n=16) or schizoaffective (n=2) psychosis (ICD-10).
N=18.
Sex: 12 M, 6F.
Interventions 1. Adjunctive carbamazepine: dose mean 567mg/day, titrated in week 1 to plasma-level of 6-12mg/ml
+ constant haloperidol dose: dose mean ~ 15mg/day, higher in this group to maintain effective plasma-
levels. N=9.
2. No additional treatment + constant haloperidol dose. N=9.
Outcomes 1. Leaving the study early.
2. Mental state (BPRS 20%, 35%, 50% reduction and mean at endpoint, PANSS positive score at
endpoint)
Unable to use:
Haloperidol plasma levels - data skewed.
Mean biperiden and chlorprothixen dose - data skewed.
Notes Jadad score = 2.
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Heßlinger 1998 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Llorca 1993
Methods Allocation: randomised - no further details.
Blindness: double - no further information.
Design: cross-over, no wash-out.
Duration: 4 X 5 week crossovers (preceeded by 5 weeks no adjunctive treatment).
Setting: in hospital.
Participants Diagnosis: treatment resistant schizophrenia patients (DSM-III-R, Kane criteria).
N=24.
Sex: 18 M, 6 F.
Age: mean ~44 years.
Interventions 1. Adjunctive carbamazepine: dose 2 weeks 200mg/day, 3 weeks 400mg/day + constant haloperidol (15-
65mg/day). N=6.
2. Adjunctive bromocriptine: dose 2.5mg/day + constant haloperidol (15-65mg/day). N=6.*
3. Adjunctive cyproheptadine: 12-24mg/day + constant haloperidol (15-65mg/day). N=6.*
4. Placebo additional treatment + constant haloperidol (15-65mg/day). N=6
Outcomes 1. Leaving the study early.
Unable to use:
Mental state (BPRS, SAPS, SANS - p values only).
Movement disorder (SAS, AIMS - p values only).
Notes Jadad score = 2.
* Data from groups 2 & 3 not used in this review.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Mair 1990
Methods Allocation: randomised - no further details.
Blinding: open.
Design: parallel.
Duration: 5 weeks.
Setting: in hospital.
Participants Diagnosis: schizophrenia & schizophrenia-like psychoses (ICD-9).
N=23.
Age: range 31-44 years.
History: ”acutely ill“, unresponsive to 5 days clozapine or haloperidol, admitted 4-9 times
Interventions 1. Adjunctive carbamazepine: dose 600mg/day + titrated dose of haloperidol or clozapine. N=13.
2. No additional treatment + titrated dose of haloperidol or clozapine. N=10
Outcomes 1. Leaving the study early.
Unable to use:
General functioning (CGI - no SD).
Mental state (BPRS - no SD).
Extrapyramidal side-effects (Webster scale - no data).
Other side-effects (FSUCL - no data).
Mean haloperidol/clozapine dose - no SD.
Notes Jadad score = 2.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Martin-Munoz 1989
Methods Allocation: randomised - no further information.
Blinding: not stated.
Design: parallel.
Duration: 18 days.
Setting: in hospital.
Participants Diagnosis: paranoid schizophrenia (RDC).
N=20.
Age: mean ~29 years.
Sex: 18 M, 2 F.
Interventions 1. Adjunctive carbamazepine: dose initially 600mg/day, adjusted to plasma-levels of 8-12ng/ml + haloperi-
dol, 30mg/day, fixed dose. N=10.
2. No additional treatment + haloperidol, 30mg/day, fixed dose. N=10
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Martin-Munoz 1989 (Continued)
Outcomes 1. Leaving the study early.
2. Mental state (20%, 35%, 50% BPRS reduction).
3. Movement disorder.
Unable to use:
Side effects (UKU-scale - no data).
Notes Jadad score = 2.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Nachshoni 1994
Methods Allocation: randomised - random allocation list.
Blinding: double - no further details.
Design: parallel.
Duration: 5 weeks.
Setting: in hospital.
Participants Diagnosis: residual schizophrenia (DSM-III-R).
N=30*.
Age: mean ~46 years.
Sex: 15 M, 13 F.
History: predominant negative symptoms, ill mean ~19 years.
Interventions 1. Adjunctive carbamazepine: dose increased to 600mg/day during week 1, then adjustment to plasma-
levels of 4-12ng/ml + 300-800 chlorpromazine equivalent antipsychotic treatment. N=15.
2. Placebo adjunctive treatment + 300-800 chlorpromazine equivalent antipsychotic treatment. N=15
Outcomes 1. Leaving the study early.
2. Mental state (20%, 35%, 50% BPRS reduction, HRSD, SANS at endpoint)
Unable to use:
EPS (SAS - no data).
Notes Jadad score = 4.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Neppe 1983
Methods Allocation: randomised - no further information.
Blinding: double - no further information.
Design: cross-over.
Duration: 2 X 6 weeks (preceeded by 3 week baseline).
Setting: in hospital.
Participants Diagnosis: schizophrenia (10), non-progressive dementia (2), rapid cycling (1) (diagnostic criteria unclear)
.
N=13*.
Age: mean ~34 years.
Sex: 8 M, 5 F.
History: chronic, ”poor-responders“, EEG abnormalities.
Interventions 1. Adjunctive carbamazepine: dose 600mg/day + various antipsychotics (constant dose). N=3.
2. Placebo adjunctive treatment + various antipsychotics (constant dose). N=6
Outcomes 1. Leaving the study early.
2. Global impression (CGI).
3. Mental state (20%, 35%, 50% BPRS reduction).
Unable to use:
General improvement (Global Assessment, OCR unpublished scales)
Notes *Data extracted for 9 subjects with schizophrenia from published data.
Jadad score = 3.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Simhandl 1996
Methods Allocation: randomised - no further details.
Blindness: double.
Design: parallel.
Duration: 8 weeks (intervention withdrawn at week 6).
Setting: not indicated.
Participants Diagnosis: schizophrenia (DSM-III-R).
N=42.
Age: mean ~35 years.
Sex: 30 M, 12 F.
History: ”chronic“, non-response to > 3 neuroleptics (2 different chemical classes) in last 2 years, duration
ill ~ 10 years
Interventions 1. Adjunctive carbamazepine: dose increased week 1-2 until plasma-levels = 15-42 micromol/L + constant
dose of antipsychotics. N=15.
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2. Lithium*: dose increasedweek 1-2until plama level = 0.6-1.2myml/L) + constant dose of antipsychotics.
N = 13.
3. Placebo + constant dose of antipsychotics. N=14.
Outcomes 1. Leaving the study early.
2. Global impression (CGI).
3. Mental state (20%, 35%, 50% BPRS reduction, SANS at endpoint)
Unable to use:
Plasma-levels of antipsychotics - skewed data.
Notes Jadad = 4.
*This group was not used in the analysis.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Svestka 1989
Methods Allocation: randomised - no further details.
Blindness: single (raters).
Design: cross-over.
Duration: 6 weeks (2 weeks placebo - 3 weeks carbamazepin/perphenazine - 1 week placebo - 3 weeks
carbamazepin/perphenazine).
Setting: hospital.
Participants Diagnosis: ICD-9 schizophrenia (n=28) or schizoaffective disorder (n=10).
History: ”acutely ill“, duration ill ~9 years.
N=38.
Age: mean ~38 years.
Sex: 30 M, 8 F (the gender of 2 people who left early is unknown)
Interventions 1. Carbamazepine, flexible dose, mean = 1374 SD = 334, N=22.
2. Perphenazine, flexible dose, mean = 53, SD = 12 . N = 18.
Then 1 week placebo and 3 week cross-over to other treatment
Outcomes 1. Leaving the study early.
2. Mental state (20%, 35%, 50% BPRS reduction and BPRS at endpoint)
3. Various side-effects.
Notes Jadad = 4.
Risk of bias
Item Authors’ judgement Description
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Allocation concealment? Unclear B - Unclear
General abbreviations:
CBZ - carbamazepine
HPL - haloperidol
EPS - Extrapyramidal side effects.
EEG - electroencephalogram
M - males
F - females
N = number
Mg = milligram
Diagnostic tools:
DSM-III-R - Diagnostic and Statistical Manual of Mental disorders, third edition,revised.
ICD-9/10 - International Classification of Diseases, ninth/tenth revision.
RDC - Research Diagnostic Criteria
Global effect scales:
CGI - Clinical Global Impression (Guy 1976 (2))
OCR - Overall Clinical Rating
Mental state scales:
BPRS - Brief Psychiatric Rating Scale (Overall and Gorham 1970)
IMPS - Inpatient Multidimensional Rating Scale (Lorr 1962)
PANSS - Positive and Negative Symptoms Scale (Kay 1987)
BRMAS - Bech-Rafaelsen Scale for Mania
MSM - Murphy Scale for Mania
SANS - Scale for Assessment of Negative Symptoms (Andreasen 1989)
SAPS - Scale for Assessment of Positive Symptoms (Andreasen 1984)
Side effect scales:
CGI - Clinical Global Impression, side effects (Guy 1976)
UKU - UKU Side effect Scale (Lingjaerde et al. 1987)
AIMS - Abnormal Involuntary Movement Scale (Guy 1976)
SAS - Simpson and Angus Scale (Simpson and Angus 1970)
FSUCL - Fischers Somatische Symptome oder Unerwünschte Effekte Check List (Fischer-Cornellson 1986)
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Arana 1986 Allocation: not randomised, A-B design.
Azorin 1986 Allocation: not randomised, A-B design.
Ballenger 1984 Allocation: not randomised, case series.
Barnes 1996 Allocation: not randomised, review.
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Bellaire 1990 Allocation: randomised.
Participants: people with schizoaffective disorders or bipolar illness.
Interventions: lithium versus carbamazepine, no placebo group
Birkheimer 1985 Allocation: not randomised, review.
Borison 1991 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: rimcazole, no carbamazepine.
Botte 1988 Allocation: not randomised, A-B design.
Cabrera 1987 Allocation: randomised.
Participants: people with schizoaffective disorders and bipolar illness.
Interventions: oxcarbazepine versus lithium, no placebo group
Cegalis 1984 Allocation: not randomised, case report.
Chouinard 1990 Allocation: not randomised, case series.
Costa 1986 Allocation: not randomised, case report.
Covell 2004 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: clozapine versus typical antipsychotics, no carbamazepine group
Dalby 1971 Allocation: not randomised, A-B design.
de Vogelaer 1981 Allocation: randomised.
Participants: very heterogeneous group of patients, some with ”behavioral disorders“, some with ”psychotic“
disorders. No clear diagnoses, study focuses on character disorders.
Interventions: not entirely clear, but probably carbamazepine or placebo were added to antipsychotic drugs
Outcomes: impossible to extract data just for people with serious mental illness. As yet, no response from
the author to a letter
Dehing 1968 Allocation: randomised (random number list).
Participants: mixed group, no data on people with schizophrenia, the focus of the study was on ’character
disorders’.
Interventions: Carbamazepine or placebo added to ongoing treatment
Outcomes: according to the authors no original data are available and therefore no single outcome parameter
can be used for this review
Denicoff 1994 Allocation: not randomised, clinical practice survey/audit.
Elphick 1985 Allocation: not randomised, A-B-A design.
Frankenburg 1988 Allocation: not randomised, case series.
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Gadow 1992 Allocation: not randomised, review.
Galletly 1997 Allocation: not randomised, case series.
Ginestet 1996 Allocation: not randomised, review.
Goncalves 1985 Allocation: randomised.
Participants: manic people, seven with bipolar disorder, five with schizoaffective disorder.
Interventions: carbamazepine versus placebo, butmost participants also received haloperidol. The trial could
therefore not be classified according to the three comparisons analysed in this review and no data could be
extracted
Greil 1997 Allocation: randomised.
Participants: people with schizoaffective disorder.
Interventions: carbamazepine versus lithium, no placebo group
Hakola 1982 Allocation: not randomised, A-B design.
Hermle 1993 Allocation: not randomised, case report.
Herrera 1987 Allocation: not randomised, A-B-A design.
Iwahashi 1995 Allocation: not randomised, case-control study.
Iwahashi 1996 Allocation: not randomised, case series.
Jann 1985 Allocation: not randomised, A-B design.
Johns 1995 Allocation: not randomised, review.
Kahn 1990 Allocation: randomised.
Participants: people with schizophrenia.
Intervention: carbamazepine plus neuroleptics versus lithium plus neuroleptics, no placebo group
Karper 1992 Allocation: not randomised, case report.
Keck 1996 Allocation: not randomised, review.
Kessler 1989 Allocation: not randomised, case series.
Kidron 1985 Allocation: randomised, cross-over.
Participants: people with schizophrenia or schizoaffective disorders and excited states.
Interventions: haloperidol + carbamazepine versus haloperidol + placebo.
Outcomes: no usable data.
Klein 1984 Allocation: randomised, parallel (participants with poor response were crossed-over at the end).
Participants: those with schizophrenia or schizoaffective disorders and excited states.
Interventions: haloperidol + carbamazepine versus haloperidol + placebo.
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Outcomes: no usable data.
Kraft 1984 Allocation: not randomised, case report.
Lambert 1987 Allocation: review.
Lapensee 1992 Allocation: not randomised, review.
Lenzi 1986 Allocation: randomised.
Participants: mixed affective and nonaffective psychoses.
Interventions: carbamazepine + chlorpromazine versus lithium + chlorpromazine, no placebo group
Llorca 1992 Allocation: not randomised, review.
Luchins 1983 Allocation: not randomised, case series.
Luchins 1984 Allocation: not randomised, case report.
Makaric 2000 Allocation: controlled clinical trial, but not randomised.
McAllister 1985 Allocation: not randomised, case series.
McKee 1989 Allocation: not randomised, case report.
Meltzer 1992 Allocation: not randomised, review.
Meshel 1967 Allocation: randomised.
Participants: people with psychosis.
Interventions: tybamate versus placebo, no carbamazepine group
Meshel 1968 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: tybamate versus placebo, no carbamazepine group
Miceli 2000 Allocation: randomised.
Participants: healthy volunteers.
Miller 1965 Allocation: unclear.
Participants: people with schizophrenia.
Interventions: hydroxyphenamate, no carbamazepine group.
Miodownik 2003 Allocation: unclear, but probably randomised.
Participants: people with schizophrenia.
Interventions: vitamin B6, no carbamazepine group.
Mokrusch 1987 Allocation: not randomised, review.
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Morinigo 1992 Allocation: randomised.
Participants: people with mania.
Mosca 1998 Allocation: randomised.
Participants: people with violent behaviour or impulsivity.
Interventions: carbamazepine versus valproate, no placebo.
Munetz 1989 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: rimcazole, no carbamazepine group.
Möller 1989 Allocation: randomised, cross-over.
Participants: people with schizophrenia or schizoaffective disorders and excited states.
Interventions: haloperidol + carbamazepine versus haloperidol + placebo.
Outcomes: no usable data.
Möller 1996 Allocation: not randomised, review.
Nasser 1990 Allocation: not randomised, case series.
Nelson 1993 Allocation: not randomised, review.
Neppe 1988a Allocation: not randomised, review.
Neppe 1988b Allocation: not randomised, review.
Neppe 1988c Allocation: not randomised, case report.
Neppe 1991 Allocation: not randomised, case series.
Nijdam 1992 Allocation: unclear.
Participants: people with mental retardation and psychoses.
Interventions: comparison of two different formulations of carbamazepine, no placebo
Okuma 1989a Allocation: alternate allocation, category C, inadequate randomisation
Okuma 1989b Allocation: not randomised, A-B design.
Ortega 1991 Allocation: randomised (aleatory numbers list generated with a computer program)
Participants: inhalant induced psychotic disorders, not schizophrenia.
Interventions: carbamazepine as a sole treatment versus haloperidol as a sole treatment
Otani 1997 Allocation: not randomised, A-B design.
Pantelis 1996 Allocation: not randomised, review.
Panu 1984 Allocation: not randomised, case series.
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Placidi 1986 Allocation: randomised.
Participants: mixed affective and nonaffective psychoses.
Intervention: carbamazepine versus lithium, no placebo.
Raitasuo 1994 Allocation: not randomised, case report.
Rankel 1988 Allocation: not randomised, case series.
Rittmannsberger 1990 Allocation: not randomised, review.
Scher 1983 Allocation: not randomised, case series.
Schulz 1990 Allocation: randomised.
Participants: people with schizophrenia.
Interventions: antipsychotics + carbamazepine versus antipsychotics versus lithium, no placebo
Simhandl 1992 Allocation: not randomised, review.
Siris 1993 Allocation: not randomised, review.
Sramek 1988 Allocation: not randomised, A-B design.
Sugerman 1970 Allocation: unclear, probably randomised.
Participants: people with schizophrenia.
Interventions: adrenochrome semicarbazone, no carbamazepine group
Svestka 1985 Allocation: not randomised, A-B design.
Svestka 1988 Allocation: not randomised, A-B design.
Tohen 1994 Allocation: not randomised, case series.
Walden 1996 Allocation: not randomised, review.
Wetterling 1987 Allocation: not randomised, A-B-A design.
Wunderlich 1983 Allocation: not randomised, A-B design.
Yassa 1983 Allocation: not randomised, case report.
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D A T A A N D A N A L Y S E S
Comparison 1. CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Leaving the study early 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.17, 6.64]
2 Relapse (by 3 months) 1 31 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.78, 1.45]
3 Mental state: 1. Less than 20%
BPRS reduction
1 31 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.75, 1.30]
4 Mental state: 2. Average
endpoint score of the BPRS at
3 months
1 27 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.46, 0.32]
5 Adverse effects 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 allergic reactions 1 31 Risk Ratio (M-H, Fixed, 95% CI) 7.44 [0.42, 132.95]
5.2 blood dyscrasia 1 31 Risk Ratio (M-H, Fixed, 95% CI) 3.19 [0.14, 72.69]
Comparison 2. CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Leaving the study early 1 38 Risk Ratio (M-H, Fixed, 95% CI) 4.52 [0.23, 88.38]
2 Mental state: 1. Categories of
reduction on BPRS scores
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 less than 20% reduction 1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.29 [0.62, 2.66]
2.2 less than 35% reduction 1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.67 [0.86, 3.24]
2.3 less than 50% reduction 1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.78, 1.92]
3 Mental state: 2. Mean BPRS at
endpoint
1 38 Mean Difference (IV, Fixed, 95% CI) 2.30 [-3.84, 8.44]
4 Adverse effects: 1. Movement
disorders
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 akathisia 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.34]
4.2 parkinsonism 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.43]
4.3 tremor 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.30 [0.01, 6.97]
4.4 use of anticholinergic
drugs
1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.23 [0.09, 0.55]
5 Adverse effects: 2. Others 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1 blurred vision 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.04, 4.55]
5.2 collapse 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.3 [0.03, 2.63]
5.3 constipation 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.04, 4.55]
5.4 dizziness 1 38 Risk Ratio (M-H, Fixed, 95% CI) 4.52 [0.23, 88.38]
5.5 dry mouth 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.45 [0.04, 4.55]
5.6 fatigue 1 38 Risk Ratio (M-H, Fixed, 95% CI) 5.4 [0.72, 40.66]
5.7 nausia 1 38 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [0.12, 62.70]
5.8 salivation 1 38 Risk Ratio (M-H, Fixed, 95% CI) 2.71 [0.12, 62.70]
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5.9 tachycardia 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.28, 2.04]
6 Subgroup analysis -
schizoaffective disorder
excluded - Mental state:
Categories of reduction on
BPRS score
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 less than 20% reduction 1 28 Risk Ratio (M-H, Fixed, 95% CI) 3.09 [1.22, 7.84]
6.2 less than 35% reduction 1 28 Risk Ratio (M-H, Fixed, 95% CI) 2.32 [1.15, 4.67]
6.3 less than 50% reduction 1 28 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.94, 2.09]
Comparison 3. ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE
TREATMENT + ANTIPSYCHOTICS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Leaving the study early 8 182 Risk Ratio (M-H, Fixed, 95% CI) 0.47 [0.16, 1.35]
2 Global state: No improvement 2 38 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.37, 0.88]
3 Mental state: 1a. General -
categories of reduction on
BPRS scores
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 less than 20% reduction 6 147 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.44, 1.07]
3.2 less than 35% reduction 6 147 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.57, 1.05]
3.3 less than 50% reduction 6 147 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.67, 1.12]
4 Mental state: 1b. General -
average BPRS endpoint score
(high = poor)
3 79 Mean Difference (IV, Random, 95% CI) 0.30 [-12.49, 13.09]
5 Mental state: 1c. General -
average BPRS endpoint score
(high = poor, skewed data)
Other data No numeric data
6 Mental state: 1d. General -
average IMPS endpoint score
(high = poor)
2 50 Mean Difference (IV, Random, 95% CI) 5.18 [-11.09, 21.44]
7 Mental state: 2a. Specific -
positive symptoms (PANSS
subscale at endpoint, high =
poor)
1 18 Mean Difference (IV, Fixed, 95% CI) 4.22 [0.75, 7.69]
8 Mental state: 2b. Specific -
positive symptoms (IMPS score
at endpoint, high = poor)
Other data No numeric data
9 Mental state: 2c. Specific -
negative symptoms (SANS at
endpoint, high = poor)
2 53 Mean Difference (IV, Fixed, 95% CI) -2.75 [-6.71, 1.22]
10 Mental state: 2d. Specific -
depression (Hamilton scale at
endpoint, high = poor)
1 26 Mean Difference (IV, Fixed, 95% CI) -0.35 [-2.20, 1.50]
11 Behaviour: Average dose of
medication used for agitation
(chlorprothixene, skewed data)
Other data No numeric data
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12 Adverse effects: 1a Movement
disorders - at least one
movement disorder
1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.14, 1.02]
13 Adverse effects: 1b. Movement
disorders - average dose
of antiparkinsonism drugs
(biperiden, skewed data)
Other data No numeric data
14 Adverse effects: 1c. Movement
disorders - average endpoint
score (SAS, high = poor, skewed
data)
Other data No numeric data
15 Adverse effects: 1d. Movement
disorders - average endpoint
TD rating (high = poor, skewed
data)
Other data No numeric data
16 Adverse effects: 2. Others 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
16.1 allergic reaction 1 41 Risk Ratio (M-H, Fixed, 95% CI) 3.79 [0.16, 87.86]
16.2 EEG deterioration 1 41 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [0.59, 7.75]
16.3 liver enzyme elevation 1 41 Risk Ratio (M-H, Fixed, 95% CI) 2.56 [0.53, 12.42]
16.4 white blood cell decline
(substantial)
1 41 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.09, 19.06]
17 Physiological effect:
Haloperidol plasma levels
Other data No numeric data
Analysis 1.1. Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE
TREATMENT, Outcome 1 Leaving the study early.
Review: Carbamazepine for schizophrenia
Comparison: 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT
Outcome: 1 Leaving the study early
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carpenter 1991 2/15 2/16 100.0 % 1.07 [ 0.17, 6.64 ]
Total (95% CI) 15 16 100.0 % 1.07 [ 0.17, 6.64 ]
Total events: 2 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
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Analysis 1.2. Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE
TREATMENT, Outcome 2 Relapse (by 3 months).
Review: Carbamazepine for schizophrenia
Comparison: 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT
Outcome: 2 Relapse (by 3 months)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carpenter 1991 13/15 13/16 100.0 % 1.07 [ 0.78, 1.45 ]
Total (95% CI) 15 16 100.0 % 1.07 [ 0.78, 1.45 ]
Total events: 13 (Treatment), 13 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
Analysis 1.3. Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE
TREATMENT, Outcome 3 Mental state: 1. Less than 20% BPRS reduction.
Review: Carbamazepine for schizophrenia
Comparison: 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT
Outcome: 3 Mental state: 1. Less than 20% BPRS reduction
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Carpenter 1991 13/15 14/16 100.0 % 0.99 [ 0.75, 1.30 ]
Total (95% CI) 15 16 100.0 % 0.99 [ 0.75, 1.30 ]
Total events: 13 (Treatment), 14 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
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Analysis 1.4. Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE
TREATMENT, Outcome 4 Mental state: 2. Average endpoint score of the BPRS at 3 months.
Review: Carbamazepine for schizophrenia
Comparison: 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT
Outcome: 4 Mental state: 2. Average endpoint score of the BPRS at 3 months
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Carpenter 1991 13 1.93 (0.36) 14 2 (0.64) 100.0 % -0.07 [ -0.46, 0.32 ]
Total (95% CI) 13 14 100.0 % -0.07 [ -0.46, 0.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Treatment Favours Control
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Analysis 1.5. Comparison 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE
TREATMENT, Outcome 5 Adverse effects.
Review: Carbamazepine for schizophrenia
Comparison: 1 CARBAMAZEPINE AS SOLE TREATMENT vs PLACEBO AS SOLE TREATMENT
Outcome: 5 Adverse effects
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 allergic reactions
Carpenter 1991 3/15 0/16 100.0 % 7.44 [ 0.42, 132.95 ]
Subtotal (95% CI) 15 16 100.0 % 7.44 [ 0.42, 132.95 ]
Total events: 3 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
2 blood dyscrasia
Carpenter 1991 1/15 0/16 100.0 % 3.19 [ 0.14, 72.69 ]
Subtotal (95% CI) 15 16 100.0 % 3.19 [ 0.14, 72.69 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
0.001 0.01 0.1 1 10 100 1000
Favours Treatment Favours Control
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Analysis 2.1. Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE
TREATMENT, Outcome 1 Leaving the study early.
Review: Carbamazepine for schizophrenia
Comparison: 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT
Outcome: 1 Leaving the study early
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Svestka 1989 2/20 0/18 100.0 % 4.52 [ 0.23, 88.38 ]
Total (95% CI) 20 18 100.0 % 4.52 [ 0.23, 88.38 ]
Total events: 2 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
0.1 0.2 0.5 1 2 5 10
Favours Treatment Favours Control
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Analysis 2.2. Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE
TREATMENT, Outcome 2 Mental state: 1. Categories of reduction on BPRS scores.
Review: Carbamazepine for schizophrenia
Comparison: 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT
Outcome: 2 Mental state: 1. Categories of reduction on BPRS scores
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 less than 20% reduction
Svestka 1989 10/20 7/18 100.0 % 1.29 [ 0.62, 2.66 ]
Subtotal (95% CI) 20 18 100.0 % 1.29 [ 0.62, 2.66 ]
Total events: 10 (Treatment), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 less than 35% reduction
Svestka 1989 13/20 7/18 100.0 % 1.67 [ 0.86, 3.24 ]
Subtotal (95% CI) 20 18 100.0 % 1.67 [ 0.86, 3.24 ]
Total events: 13 (Treatment), 7 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
3 less than 50% reduction
Svestka 1989 15/20 11/18 100.0 % 1.23 [ 0.78, 1.92 ]
Subtotal (95% CI) 20 18 100.0 % 1.23 [ 0.78, 1.92 ]
Total events: 15 (Treatment), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 2.3. Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE
TREATMENT, Outcome 3 Mental state: 2. Mean BPRS at endpoint.
Review: Carbamazepine for schizophrenia
Comparison: 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT
Outcome: 3 Mental state: 2. Mean BPRS at endpoint
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Svestka 1989 20 36.7 (10.1) 18 34.4 (9.2) 100.0 % 2.30 [ -3.84, 8.44 ]
Total (95% CI) 20 18 100.0 % 2.30 [ -3.84, 8.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 2.4. Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE
TREATMENT, Outcome 4 Adverse effects: 1. Movement disorders.
Review: Carbamazepine for schizophrenia
Comparison: 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT
Outcome: 4 Adverse effects: 1. Movement disorders
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 akathisia
Svestka 1989 0/20 3/18 100.0 % 0.13 [ 0.01, 2.34 ]
Subtotal (95% CI) 20 18 100.0 % 0.13 [ 0.01, 2.34 ]
Total events: 0 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
2 parkinsonism
Svestka 1989 0/20 16/18 100.0 % 0.03 [ 0.00, 0.43 ]
Subtotal (95% CI) 20 18 100.0 % 0.03 [ 0.00, 0.43 ]
Total events: 0 (Treatment), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.57 (P = 0.010)
3 tremor
Svestka 1989 0/20 1/18 100.0 % 0.30 [ 0.01, 6.97 ]
Subtotal (95% CI) 20 18 100.0 % 0.30 [ 0.01, 6.97 ]
Total events: 0 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.75 (P = 0.45)
4 use of anticholinergic drugs
Svestka 1989 4/20 16/18 100.0 % 0.23 [ 0.09, 0.55 ]
Subtotal (95% CI) 20 18 100.0 % 0.23 [ 0.09, 0.55 ]
Total events: 4 (Treatment), 16 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.28 (P = 0.0010)
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
43Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.5. Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE
TREATMENT, Outcome 5 Adverse effects: 2. Others.
Review: Carbamazepine for schizophrenia
Comparison: 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT
Outcome: 5 Adverse effects: 2. Others
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 blurred vision
Svestka 1989 1/20 2/18 100.0 % 0.45 [ 0.04, 4.55 ]
Subtotal (95% CI) 20 18 100.0 % 0.45 [ 0.04, 4.55 ]
Total events: 1 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 collapse
Svestka 1989 1/20 3/18 100.0 % 0.30 [ 0.03, 2.63 ]
Subtotal (95% CI) 20 18 100.0 % 0.30 [ 0.03, 2.63 ]
Total events: 1 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
3 constipation
Svestka 1989 1/20 2/18 100.0 % 0.45 [ 0.04, 4.55 ]
Subtotal (95% CI) 20 18 100.0 % 0.45 [ 0.04, 4.55 ]
Total events: 1 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
4 dizziness
Svestka 1989 2/20 0/18 100.0 % 4.52 [ 0.23, 88.38 ]
Subtotal (95% CI) 20 18 100.0 % 4.52 [ 0.23, 88.38 ]
Total events: 2 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
5 dry mouth
Svestka 1989 1/20 2/18 100.0 % 0.45 [ 0.04, 4.55 ]
Subtotal (95% CI) 20 18 100.0 % 0.45 [ 0.04, 4.55 ]
Total events: 1 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
6 fatigue
Svestka 1989 6/20 1/18 100.0 % 5.40 [ 0.72, 40.66 ]
Subtotal (95% CI) 20 18 100.0 % 5.40 [ 0.72, 40.66 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 6 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
7 nausia
Svestka 1989 1/20 0/18 100.0 % 2.71 [ 0.12, 62.70 ]
Subtotal (95% CI) 20 18 100.0 % 2.71 [ 0.12, 62.70 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
8 salivation
Svestka 1989 1/20 0/18 100.0 % 2.71 [ 0.12, 62.70 ]
Subtotal (95% CI) 20 18 100.0 % 2.71 [ 0.12, 62.70 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
9 tachycardia
Svestka 1989 5/20 6/18 100.0 % 0.75 [ 0.28, 2.04 ]
Subtotal (95% CI) 20 18 100.0 % 0.75 [ 0.28, 2.04 ]
Total events: 5 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
0.001 0.01 0.1 1 10 100 1000
Favours treatment Favours control
45Carbamazepine for schizophrenia (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.6. Comparison 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE
TREATMENT, Outcome 6 Subgroup analysis - schizoaffective disorder excluded - Mental state: Categories of
reduction on BPRS score.
Review: Carbamazepine for schizophrenia
Comparison: 2 CARBAMAZEPINE AS SOLE TREATMENT vs ANTIPSYCHOTICS AS SOLE TREATMENT
Outcome: 6 Subgroup analysis - schizoaffective disorder excluded - Mental state: Categories of reduction on BPRS score
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 less than 20% reduction
Svestka 1989 8/11 4/17 100.0 % 3.09 [ 1.22, 7.84 ]
Subtotal (95% CI) 11 17 100.0 % 3.09 [ 1.22, 7.84 ]
Total events: 8 (Treatment), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.38 (P = 0.017)
2 less than 35% reduction
Svestka 1989 9/11 6/17 100.0 % 2.32 [ 1.15, 4.67 ]
Subtotal (95% CI) 11 17 100.0 % 2.32 [ 1.15, 4.67 ]
Total events: 9 (Treatment), 6 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.35 (P = 0.019)
3 less than 50% reduction
Svestka 1989 10/11 11/17 100.0 % 1.40 [ 0.94, 2.09 ]
Subtotal (95% CI) 11 17 100.0 % 1.40 [ 0.94, 2.09 ]
Total events: 10 (Treatment), 11 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.094)
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Analysis 3.1. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 1 Leaving the study early.
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 1 Leaving the study early
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dose 1987 1/18 6/23 51.8 % 0.21 [ 0.03, 1.61 ]
He linger 1998 2/9 0/9 4.9 % 5.00 [ 0.27, 91.52 ]
Llorca 1993 0/6 0/6 Not estimable
Mair 1990 0/13 0/10 Not estimable
Martin-Munoz 1989 0/10 0/10 Not estimable
Nachshoni 1994 0/15 0/15 Not estimable
Neppe 1983 0/3 2/6 17.9 % 0.35 [ 0.02, 5.62 ]
Simhandl 1996 0/15 2/14 25.4 % 0.19 [ 0.01, 3.60 ]
Total (95% CI) 89 93 100.0 % 0.47 [ 0.16, 1.35 ]
Total events: 3 (Treatment), 10 (Control)
Heterogeneity: Chi2 = 3.54, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.40 (P = 0.16)
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Analysis 3.2. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 2 Global state: No improvement.
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 2 Global state: No improvement
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Neppe 1983 0/3 5/6 21.1 % 0.16 [ 0.01, 2.19 ]
Simhandl 1996 10/15 14/14 78.9 % 0.68 [ 0.47, 0.98 ]
Total (95% CI) 18 20 100.0 % 0.57 [ 0.37, 0.88 ]
Total events: 10 (Treatment), 19 (Control)
Heterogeneity: Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 2.56 (P = 0.010)
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Analysis 3.3. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 3 Mental state: 1a. General - categories of
reduction on BPRS scores.
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 3 Mental state: 1a. General - categories of reduction on BPRS scores
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 less than 20% reduction
Dose 1987 3/18 8/23 24.6 % 0.48 [ 0.15, 1.55 ]
He linger 1998 3/9 1/9 3.5 % 3.00 [ 0.38, 23.68 ]
Martin-Munoz 1989 0/10 0/10 Not estimable
Nachshoni 1994 10/15 10/15 35.0 % 1.00 [ 0.60, 1.66 ]
Neppe 1983 1/3 5/6 11.7 % 0.40 [ 0.08, 2.06 ]
Simhandl 1996 2/15 7/14 25.3 % 0.27 [ 0.07, 1.07 ]
Subtotal (95% CI) 70 77 100.0 % 0.69 [ 0.44, 1.07 ]
Total events: 19 (Treatment), 31 (Control)
Heterogeneity: Chi2 = 6.63, df = 4 (P = 0.16); I2 =40%
Test for overall effect: Z = 1.67 (P = 0.096)
2 less than 35% reduction
Dose 1987 3/18 10/23 22.8 % 0.38 [ 0.12, 1.19 ]
He linger 1998 3/9 1/9 2.6 % 3.00 [ 0.38, 23.68 ]
Martin-Munoz 1989 2/10 1/10 2.6 % 2.00 [ 0.21, 18.69 ]
Nachshoni 1994 13/15 14/15 36.4 % 0.93 [ 0.73, 1.18 ]
Neppe 1983 2/3 5/6 8.7 % 0.80 [ 0.33, 1.92 ]
Simhandl 1996 6/15 10/14 26.9 % 0.56 [ 0.28, 1.13 ]
Subtotal (95% CI) 70 77 100.0 % 0.78 [ 0.57, 1.05 ]
Total events: 29 (Treatment), 41 (Control)
Heterogeneity: Chi2 = 6.81, df = 5 (P = 0.23); I2 =27%
Test for overall effect: Z = 1.63 (P = 0.10)
3 less than 50% reduction
Dose 1987 2/18 15/23 28.9 % 0.17 [ 0.04, 0.65 ]
He linger 1998 7/9 1/9 2.2 % 7.00 [ 1.07, 45.90 ]
Martin-Munoz 1989 2/10 1/10 2.2 % 2.00 [ 0.21, 18.69 ]
Nachshoni 1994 14/15 14/15 30.7 % 1.00 [ 0.83, 1.21 ]
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(. . . Continued)
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Neppe 1983 3/3 5/6 8.8 % 1.11 [ 0.65, 1.90 ]
Simhandl 1996 10/15 12/14 27.2 % 0.78 [ 0.51, 1.18 ]
Subtotal (95% CI) 70 77 100.0 % 0.86 [ 0.67, 1.12 ]
Total events: 38 (Treatment), 48 (Control)
Heterogeneity: Chi2 = 14.31, df = 5 (P = 0.01); I2 =65%
Test for overall effect: Z = 1.11 (P = 0.27)
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Analysis 3.4. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 4 Mental state: 1b. General - average BPRS
endpoint score (high = poor).
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 4 Mental state: 1b. General - average BPRS endpoint score (high = poor)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dose 1987 17 27.5 (7.9) 17 36.5 (9.8) 36.6 % -9.00 [ -14.98, -3.02 ]
He linger 1998 9 41.78 (14.13) 9 28.56 (8.02) 31.2 % 13.22 [ 2.61, 23.83 ]
Simhandl 1996 15 37.67 (6.94) 12 39.33 (16.37) 32.1 % -1.66 [ -11.57, 8.25 ]
Total (95% CI) 41 38 100.0 % 0.30 [ -12.49, 13.09 ]
Heterogeneity: Tau2 = 106.97; Chi2 = 12.89, df = 2 (P = 0.002); I2 =84%
Test for overall effect: Z = 0.05 (P = 0.96)
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Analysis 3.5. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 5 Mental state: 1c. General - average BPRS
endpoint score (high = poor, skewed data).
Mental state: 1c. General - average BPRS endpoint score (high = poor, skewed data)
Study
Martin-Munoz 1989 1. Carbamazepine + antipsychotics: mean 8.6, SD 9.6, N=10.
2. Placebo + antipsychotics: mean 7.4, SD 4.7, N=10.
Nachshoni 1994 1. Carbamazepine + antipsychotics: mean 5.0, SD 2.70, N=15.
2. Placebo + antipsychotics: mean 5.1, SD 1.6, N=15.
Neppe 1983 1. Carbamazepine + antipsychotics: mean 14.7, SD 5.8, N=3.
2. Placebo + antipsychotics: mean 22.0, SD 13.4, N=4.
Analysis 3.6. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 6 Mental state: 1d. General - average IMPS
endpoint score (high = poor).
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 6 Mental state: 1d. General - average IMPS endpoint score (high = poor)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Dose 1987 16 8.9 (7) 16 12 (6) 50.1 % -3.10 [ -7.62, 1.42 ]
He linger 1998 9 42 (5.1) 9 28.5 (5.4) 49.9 % 13.50 [ 8.65, 18.35 ]
Total (95% CI) 25 25 100.0 % 5.18 [ -11.09, 21.44 ]
Heterogeneity: Tau2 = 132.06; Chi2 = 24.08, df = 1 (P<0.00001); I2 =96%
Test for overall effect: Z = 0.62 (P = 0.53)
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Analysis 3.7. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 7 Mental state: 2a. Specific - positive symptoms
(PANSS subscale at endpoint, high = poor).
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 7 Mental state: 2a. Specific - positive symptoms (PANSS subscale at endpoint, high = poor)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
He linger 1998 9 14.44 (4.5) 9 10.22 (2.81) 100.0 % 4.22 [ 0.75, 7.69 ]
Total (95% CI) 9 9 100.0 % 4.22 [ 0.75, 7.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours Treatment Favours Control
Analysis 3.8. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 8 Mental state: 2b. Specific - positive
symptoms (IMPS score at endpoint, high = poor).
Mental state: 2b. Specific - positive symptoms (IMPS score at endpoint, high = poor)
Study
Dose 1987 1. Carbamazepine + antipsychotics: mean 4.9, SD 6.4, N=16.
2. Placebo + antipsychotics: mean 7.5, SD 8.1, N=16.
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Analysis 3.9. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 9 Mental state: 2c. Specific - negative
symptoms (SANS at endpoint, high = poor).
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 9 Mental state: 2c. Specific - negative symptoms (SANS at endpoint, high = poor)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nachshoni 1994 13 67 (13.77) 13 67.93 (11.08) 17.0 % -0.93 [ -10.54, 8.68 ]
Simhandl 1996 15 13.13 (4.16) 12 16.25 (6.73) 83.0 % -3.12 [ -7.47, 1.23 ]
Total (95% CI) 28 25 100.0 % -2.75 [ -6.71, 1.22 ]
Heterogeneity: Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 10 Mental state: 2d. Specific - depression
(Hamilton scale at endpoint, high = poor).
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 10 Mental state: 2d. Specific - depression (Hamilton scale at endpoint, high = poor)
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Nachshoni 1994 13 4.79 (2.36) 13 5.14 (2.45) 100.0 % -0.35 [ -2.20, 1.50 ]
Total (95% CI) 13 13 100.0 % -0.35 [ -2.20, 1.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 11 Behaviour: Average dose of medication
used for agitation (chlorprothixene, skewed data).
Behaviour: Average dose of medication used for agitation (chlorprothixene, skewed data)
Study
Dose 1987 1. Carbamazepine + antipsychotics: mean dose 40mg/day, SD 36. N=17.
2. Placebo + antipsychotics: mean dose 63mg/day, SD 49. N=17
Heßlinger 1998 1. Carbamazepine + haloperidol: mean chlorprothixene dose 182mg/day, SD 30.1. N=9.
2. Placebo + haloperidol: mean dose 21.6mg/day, SD 5.8. N=9.
Analysis 3.12. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 12 Adverse effects: 1a Movement disorders - at
least one movement disorder.
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 12 Adverse effects: 1a Movement disorders - at least one movement disorder
Study or subgroup Treatment control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Martin-Munoz 1989 3/10 8/10 100.0 % 0.38 [ 0.14, 1.02 ]
Total (95% CI) 10 10 100.0 % 0.38 [ 0.14, 1.02 ]
Total events: 3 (Treatment), 8 (control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.054)
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Analysis 3.13. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 13 Adverse effects: 1b. Movement disorders -
average dose of antiparkinsonism drugs (biperiden, skewed data).
Adverse effects: 1b. Movement disorders - average dose of antiparkinsonism drugs (biperiden, skewed data)
Study
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Adverse effects: 1b. Movement disorders - average dose of antiparkinsonism drugs (biperiden, skewed data) (Continued)
Dose 1987 1. Carbamazepine + antipsychotics: mean dose 1.3mg/day, SD 1.6. N=17.
2. Placebo + antipsychotics: mean dose 3.8 mg/day, SD 2.3. N=17
Heßlinger 1998 1. Carbamazepine + haloperidol: mean dose 3.9mg/day, SD 0.8. N=9.
2. Placebo + haloperidol: mean dose 2.9 mg/day, SD 1.0 N=9.
Simhandl 1996 1. Carbamazepine + antipsychotics: mean dose 2.67mg/day, SD 2.89. N=15.
2. Placebo + antipsychotics: mean dose 2.67 mg/day, SD 4.62. N=12
Analysis 3.14. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 14 Adverse effects: 1c. Movement disorders -
average endpoint score (SAS, high = poor, skewed data).
Adverse effects: 1c. Movement disorders - average endpoint score (SAS, high = poor, skewed data)
Study
Dose 1987 1. Carbamazepine + antipsychotics: mean 1.03, SD 0.86. N=17.
2. Placebo + antipsychotics: mean 2.84, SD 2.18. N=17.
Nachshoni 1994 1. Carbamazepine + antipsychotics: mean 0.9, SD 0.9. N=13.
2. Placebo + antipsychotics: mean 0.4, SD 0.5. N=13.
Simhandl 1996 1. Carbamazepine + antipsychotics: mean 0.27, SD 0.19. N=15.
2. Placebo + antipsychotics: mean 0.31, SD 0.35. N=12.
Analysis 3.15. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 15 Adverse effects: 1d. Movement disorders -
average endpoint TD rating (high = poor, skewed data).
Adverse effects: 1d. Movement disorders - average endpoint TD rating (high = poor, skewed data)
Study
Simhandl 1996 1. Carbamazepine + antipsychotics: mean 7.1, SD 0.2. N=15.
2. Placebo + antipsychotics: mean 13.1, SD 14.2. N=12.
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Analysis 3.16. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 16 Adverse effects: 2. Others.
Review: Carbamazepine for schizophrenia
Comparison: 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS
Outcome: 16 Adverse effects: 2. Others
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 allergic reaction
Dose 1987 1/18 0/23 100.0 % 3.79 [ 0.16, 87.86 ]
Subtotal (95% CI) 18 23 100.0 % 3.79 [ 0.16, 87.86 ]
Total events: 1 (Treatment), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
2 EEG deterioration
Dose 1987 5/18 3/23 100.0 % 2.13 [ 0.59, 7.75 ]
Subtotal (95% CI) 18 23 100.0 % 2.13 [ 0.59, 7.75 ]
Total events: 5 (Treatment), 3 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
3 liver enzyme elevation
Dose 1987 4/18 2/23 100.0 % 2.56 [ 0.53, 12.42 ]
Subtotal (95% CI) 18 23 100.0 % 2.56 [ 0.53, 12.42 ]
Total events: 4 (Treatment), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.24)
4 white blood cell decline (substantial)
Dose 1987 1/18 1/23 100.0 % 1.28 [ 0.09, 19.06 ]
Subtotal (95% CI) 18 23 100.0 % 1.28 [ 0.09, 19.06 ]
Total events: 1 (Treatment), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
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Analysis 3.17. Comparison 3 ADJUNCTIVE CARBAMAZEPINE + ANTIPSYCHOTICS vs PLACEBO/NO
ADJUNCTIVE TREATMENT + ANTIPSYCHOTICS, Outcome 17 Physiological effect: Haloperidol plasma
levels.
Physiological effect: Haloperidol plasma levels
Study
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Physiological effect: Haloperidol plasma levels (Continued)
Dose 1987 1. Carbamazepine + antipsychotics: mean level 5.8 (mg haloperidol/d)/(microgms/L haloperidol), SEM 3.3. N=
17.
2. Placebo + antipsychotics: mean level 3.1 (mg haloperidol/d)/(microgms/L haloperidol), SEM 1.65. N=17
Heßlinger 1998 1. Carbamazepine + haloperidol: mean haloperidol level change -3.8 ng/ml, SD 3.0. N=9 (~45% decrease).
2. Placebo + haloperidol: mean haloperidol level change 1.9 ng/ml, SD 2.3. N=9 (~51% increase)
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